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Foreword  
 
 
Since 2001, SIRUS has been the Norwegian Focal Point for the European Monitoring 
Centrefor Drugs and Drug Addiction - EMCDDA. All 30 member countries submit an annual 
national report. In addition, a number of standardised tables and questionnaires, mainly 
comprising epidemiological data, are submitted separately every year. Taken together, this 
represents our main contribution to the annual European Drug Report from the EMCDDA.  
As in previous years, this 13th national report on the drug situation in Norway has been drawn 
up in accordance with the common reporting guidelines. Because the report is intended to 
focus on news and to primarily cover important developments and trends, it may appear rather 
fragmentary. However, we hope that the content will prove useful to readers who wish to 
familiarise themselves with the drugs situation in Norway. SIRUS wishes to express its 
gratitude to all external partners and public institutions that helped in the preparation of the 
report. Our thanks go in particular to the co-authors who have made textual contributions. 
 
 
       Oslo, December 2013 
       Odd Hordvin  
       Head of Focal Point  
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Summary – some major developments and trends 
 
Legal framework: Generic scheduling of substances  
New Regulations relating to Narcotics entered into force on 14 February 2013. The principle 
of generic scheduling has now been introduced as a supplement to individual listing. Ten 
groups of substances, seven of them describing synthetic cannabinoids, are included on the 
list of controlled substances. These groups cover many of the newly developed psychoactive 
substances that have been discovered since 2011. 
Legal framework: Possession and use of doping substances criminalised  
From 1 July 2013, amendments to the Act relating to Medicinal Products were introduced 
with a view to harmonising legislation on doping and drugs. The acquisition, possession and 
use of doping substances without lawful access was thereby made a criminal offence. 
New white paper 
The white paper on drugs and alcohol policy (Report no 30 to the Storting (2011–2012)) was 
considered by the Storting(Parliament) in March 2013. The white paper sets out the political 
goals for a comprehensive drugs and alcohol policy: prevention and early intervention; 
coordination – services working together; greater competence and better quality of services; 
help for those with severe dependency; reducing the number of overdose fatalities; efforts 
aimed at next-of-kin and at reducing harm to third parties. 
Strategy relating to overdoses  
Norway ranks high on the European statistics for overdoses, although there is uncertainty 
attached to the data on which the comparison is based, including different interpretations at 
the national level of causes of death. In the white paper on drugs and alcohol policy, the 
Government proposed a national strategy to combat overdose deaths. The Storting has 
endorsed this proposal and adopted a zero-vision goal for overdose deaths. On this basis, 
NOK 10 million was allocated for 2013 and 2014 for the development of a five-year overdose 
strategy. The Directorate of Health will complete a comprehensive plan setting out several 
measures. The measures are planned and will be implemented in cooperation with user and 
next-of-kin organisations, municipalities and other involved parties. As part of this effort, the 
Norwegian Centre for Addiction Research (SERAF) has been assigned the task of initiating a 
trial project in Oslo and Bergen that involves distributing naloxone nasal spray to users and 
next-of-kin. SIRUS will carry out a follow-up evaluation of the implementation of the 
strategy. 
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Injecting drug use – stable  
Estimates of the number of injecting drug users have been revised from and including 2013. 
The mortality multiplier method is still used. It estimates the number of injecting drug users 
by dividing the number of drug-related deaths by the likelihood of dying of a drug-related 
diagnosis. The number of injecting drug users in 2011 was estimated to be between 7,300 and 
10,300. Previous national reports have shown that the number of injecting users increased 
from the 1970s until 2001, followed by a reduction until 2003. The figure has since remained 
stable. 
Treatment – high number of patients and admissions  
According to the National patient register, a total of 16,778 patients received treatment during 
the 2012 calendar year for drug problems as their primary condition. Seven out of ten were 
men. The number includes patients in both in-patient and outpatient treatment, and the sample 
is based on ICD-10 F codes. The biggest group (39%) had problems relating to the use of 
opioids as their primary diagnosis. The second biggest diagnosis category was multiple drug 
use, followed by cannabis and stimulants.  
As for those who started treatment for drug-related problems in 2012, reports were submitted 
from 146 units concerning a total of 8,891 patients (2011: 8,817 patients from 159 units), 
3,691 in in-patient and 5,200 in outpatient treatment, including opioid substitution treatment -
OST. The comparative figures for 2011 were 3,921 and 4,896. Around 69 per cent of patients 
starting treatment were men. The average age of patients was around 34 years for men and 36 
years for women. Problems with opioids were the most frequently reported diagnosis in both 
outpatient and in-patient treatment where the primary drug was identified. The second most 
frequent diagnosis was the use of stimulants for patients in residential treatment and cannabis 
upon admission to outpatient treatment. The latter accounted for as many as 31 per cent of the 
patients where the primary drug was identified. It is also notable that the proportion with 
cannabis as their primary drug upon admission to in-patient treatment had increased to 18 per 
cent, while it was 11 per cent in 2011. 
Drug-induced deaths – some increase in numbers, fewer deaths caused by heroin.  
Of the 262 drug-related deaths in 2011 that were recorded by Statistics Norway, 207 deaths 
involved opioids with or without additional drugs, 74 deaths were due to heroin, 47 deaths 
were recorded with methadone poisoning as the underlying cause, and 68 with other opioids, 
either as poisoning or opioid dependency. In addition, there were 18 deaths coded as related to 
other synthetic opioids’. Many of the drug-related deaths are believed to be due to extensive 
multiple drug use.  
Since 2007, the average strength of heroin seized by the police in Norway has decreased from 
36 per cent to around 15 per cent. During the same period, the proportion of heroin as the 
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main intoxicant has been almost halved. However, more than four out of five drug-related 
deaths are still due to opioids. It seems that a gradual change may be taking place in the 
preference for and/or availability of opioids among opioid users, and that this is also reflected 
in causes of death. Amphetamine and/or methamphetamine and/or cocaine were detected in 
11 per cent of the deaths. 
Reported crimes – increasing numbers 
According to Statistics Norway, a total of 45,900 drug crimes were reported in 2012. This is 
3,100 more than in 2011, and the highest number recorded since 2001. The number includes 
violations of both the General Civil Penal Code and the Act relating to Medicinal Products. In 
total, around 21,600 drug crimes pursuant to Section 162 of the General Civil Penal Code, 
including aggravated drug crimes, were reported. This is almost on a par with 2010, the peak 
year in terms of reported drug crimes. The nearly 23,500 violations of the provision of the Act 
relating to Medicinal Products concerning use and possession was the highest number since 
the early 2000s. The increase was greatest by far in Oslo. 
Penal sanctions  
The number of penal sanctions where drug crime was the primary offence was 15,700 in 
2011. This is just over 5 per cent more than in 2010 and as much as 22 per cent more than in 
2009. Never before have so many penal sanctions been recorded with drug crime as the 
primary offence: in 2011, they accounted for more than 47 per cent of all penal sanctions in 
criminal cases. Seen in relation to the increase in population, however, the number of penal 
sanctions for drug crimes is still lower than in the peak year of 2001. Drug crime as the 
primary offence was the reason for nearly 2,000 of the unconditional prison sentences (both 
unconditional and partly unconditional/partly suspended). Of the offenders (cases, not 
persons), 205 were sentenced to imprisonment for use as the primary offence. This represents 
more than a twofold increase from 2009. However, these are often complex cases, where 
other, less serious offences are taken into consideration in the overall sentencing. 
Drug markets 
Measured by seizures, the most common illegal substances are geographically widespread. In 
2012, all the 27 police districts made seizures of cannabis, BZD and amphetamines, whereas 
cocaine was seized in 25 districts and heroin in 23, which is quite similar to the situation in 
2011. It must be emphasised, however, that the quantities vary greatly between the different 
police districts. For cocaine and heroin, the amounts seized in some districts are often very 
small. The biggest markets are still the Oslo area and its surrounding regions, and in the 
counties of Hordaland and Rogaland, including the cities of Bergen and Stavanger. Moreover, 
the customs authorities in Østfold county make many large seizures, which can largely be 
explained by its proximity to the most important border crossings to Sweden, where large 
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parts of the drug trafficking to Norway take place by road and by train from Denmark and the 
Continent. 
Seizures  
Although the number of drug cases increased for the fourth year in a row, the seizures do not 
represent record-high quantities, except in the case of benzodiazepines. While the number of 
seizures of hash is relatively stable, there is a marked increase in seizures of marijuana and 
cannabis plants. In the early 2000s, hash accounted for approximately 90 per cent of cannabis 
seizures, but it now accounts for 70 per cent, while marijuana and cannabis plants account for 
as much as 30 per cent. This development may be due to extensive and increasing production 
of cannabis in Norway. 
The number of seizures of amphetamine/methamphetamine is still high. Although slightly 
fewer seizures were made in 2012 than in 2011, a larger quantity of amphetamine/ 
methamphetamine was seized than in the two preceding years. Fewer seizures were made in 
2012 than 2011 of PMMA, which is sold on the amphetamine market and has caused a 
number of deaths. 
Fewer seizures were also made of heroin than in the preceding years. Some large seizures 
resulted in higher quantities, however. 
There are still great variations in the purity of amphetamine/methamphetamine, heroin and 
cocaine, from very weak (< 1%) to completely pure qualities. There is also great variation in 
typical street seizures. 
Even though traditional drugs dominate the drug market, new synthetic substances are seized 
all the time. In 2012, Kripos identified 30 new substances that had previously not been seized 
in Norway. Synthetic cannabinoids dominate among the new synthetic substances seized in 
the past two or three years. Of these, AM-2201 is currently the one most frequently seized. 
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1 Drug policy: legislation, strategies and economic 
analysis  
 
1.1 Legal framework 
New Regulations relating to Narcotics1 entered into force on 14 February 2013. The principle 
of generic scheduling is now introduced as a supplement to individual listing. Ten groups of 
substances, seven of them describing synthetic cannabinoids, are included on the list of 
controlled substances. These groups cover many of the newly developed psychoactive 
substances that have been discovered since 2011. The new regulations make it easier to 
determine whether a substance shall be deemed to be a narcotic substance. This means that it 
will be possible to a greater extent to be ahead of developments when it comes to new 
synthetic substances on the market.  
From 1 July 2013, amendments to the Act relating to Medicinal Products were introduced 
with a view to harmonising legislation on doping and drugs and in order to clarify society’s 
attitude to the use of doping. The acquisition, possession and use of doping substances 
without lawful access was thereby made a criminal offence. As with the use of drugs, the use 
of doping is, in principle, regarded as a health problem that should primarily be met with 
health care, preferably in the form of alternative penal sanctions.  
A proposal to amend the Drug Injection Rooms Act (Act No 64 of 2 July 2004 relating to a 
Trial Scheme of Premises for Drug Injection) and pertaining Regulations No 1661 of 17 
December 2004 was distributed for consultation, with a deadline for responding of 31 October 
2013. If adopted, this will allow municipalities to permit the inhalation of heroin in injection 
rooms.  
1.2 National action plan, strategy, evaluation and coordination 
The white paper on drugs and alcohol policy (Report no 30 to the Storting (2011–2012)) was 
considered by the Storting in March 2013; cf. Recommendation No 207 to the Storting (2012–
2013). The white paper sets out the political goals for a comprehensive drugs and alcohol 
policy:  
 
 
1 http://www.regjeringen.no/upload/HOD/Dokumenter%20FHA/Narkotikaforskrift.pdf 
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• Prevention and early intervention 
• Coordination – services working together 
• Greater competence and better quality of services 
• Help for those with severe dependency – reducing the number of overdose fatalities 
• Efforts aimed at next-of-kin and at reducing harm to third parties. 
The overriding goal of Norway’s drugs and alcohol policy is to reduce the negative 
consequences of drug and alcohol use for individuals and for society as a whole. The Ministry 
of Health and Care Services has overall responsibility for drugs and alcohol policy and for 
coordinating the presentation and follow-up of the white papers in cooperation with a total of 
11 ministries.  
The escalation plan for the drugs and alcohol field (see NR2 2011 and 2012) was concluded in 
2012, but a number of measures from the plan will be continued. Where efforts need to be 
strengthened, the plan will be succeeded by strategies in the fields of public health, overdoses, 
competence and the implementation of treatment for drug and alcohol-related problems and 
mental health through the Coordination Reform.3  
Extensive efforts have been made in the drugs and alcohol field in recent years, both in the 
municipalities and in the specialist health service. However, user organisations and experts 
point out that the services must be involved at an earlier stage and that the availability of 
services must be improved. Lack of coordination is another important challenge. Many of 
those who seek help for abuse problems meet new obstacles when responsibility for further 
follow-up is transferred to a new level and new services. The help services are perceived by 
many as fragmented. This is a problem both within and between sectors and levels. Providing 
problem drug and alcohol users with good, individually adapted municipal follow-up services 
is also a challenge, especially in the housing and recreational context.  
Increased preventive efforts  
The white paper on drugs and alcohol policy specifies the preventive efforts to be made in the 
drugs and alcohol field. Preventive efforts must also, and not least, be seen in conjunction 
with general preventive measures targeting the population as a whole as set out in public 
health policy. The public health strategy is described in the white paper on public health 
(Report No 34 to the Storting (2012–2013): ‘Folkehelsemeldingen:4 God helse – felles ansvar 
2 NR- National Report  
3 Report No 47 (2008–2009) The Coordination Reform. Proper treatment – at the right place and right time. 
 
4 http://www.regjeringen.no/nb/dep/hod/dok/regpubl/stmeld/2012-2013/meld-st-34-
20122013.html?showdetailedtableofcontents=true&id=723818 
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(‘The Public Health Report: Good health – a shared responsibility’ – in Norwegian only). The 
Government’s goals for public health work are as follows: 
1. Norway shall be among the top three countries in the world in terms of life expectancy 
2. The population shall enjoy more years of life in good health and well-being and 
experience less social inequalities in relation to health 
As part of the follow-up of the Public Health Report, the Government will further develop 
performance goals and indicators with a view to following up the goals of its public health 
policy, including mental health and drug and alcohol problems. Systematic development of 
public health work is also planned. Among other things, a report will be presented to the 
Storting every four years on the status of and further work on achieving Norway’s public 
health goals. The Norwegian Institute of Public Health and the Directorate of Health will 
prepare reports that can be read as the basis for a political status assessment. 
The Public Health Report emphasises the close connection between the social inequalities in 
health and welfare development and differences in living conditions and income. Public 
health policy shall build on the Norwegian welfare model of universal welfare benefits, the 
work approach, participation and inclusion. Knowledge about the importance of social capital 
and social support shall be improved. Early intervention produces good results. One of the 
biggest challenges in the drugs and alcohol field is therefore to ensure early detection and 
intervention when needed. An inter-sectorial approach is essential in this work. 
By upholding the prohibition on possession and use, the Government wishes to send a clear 
message that illegal use of drugs is not socially acceptable. At the same time, it is important to 
comply with the obligations under international law that follow from the three conventions on 
drugs that Norway has ratified. The use of drugs shall, in principle, be seen as a health issue, 
and people who use drugs shall primarily be met with health care. That will also be Norway’s 
position at international meetings and negotiations.  
Mobilisation against doping 
Doping as a social problem shall be an integrated part of Norway’s drugs and alcohol policy. 
In addition to providing a legal basis for the prohibition on use and possession, as mentioned 
in Chapter 1.1, the Government is also mobilising against doping by increasing knowledge 
and focusing on prevention and good treatment services. The Directorate of Health has been 
given a clear responsibility for integrating doping in its preventive work. This applies to both 
early intervention and general prevention.  
Treatment  
Data from the Norwegian National Patient Register on interdisciplinary specialist treatment 
(IST) for 2012 show a slight increase in the number of patients compared with 2011, when 
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approximately 25,000 people received treatment for drug or alcohol-related problems. This 
includes patients with both drug and alcohol problems. In addition, a considerable number of 
patients with a psychiatric primary diagnosis were treated by the mental health service. 
Figures from BrukerPlan5 for 2012 show that approximately 30,000 persons above the age of 
18 receive municipal help for drug and alcohol problems. 
Dependency on alcohol or drugs shall be treated as a chronic illness, and a need for long-term, 
and often life-long, follow-up must be expected. The municipal services are the ‘pillar’ in the 
services provided throughout the course of treatment, in close collaboration with a supporting 
and more outreach-based, available and flexible specialist health service when required. The 
services shall be adapted to the individual user’s needs and are designed to enable them to 
cope, enjoy good health and a dignified life situation.  
Chief responsibility shall rest with the local level. Extensive use of outreach/ambulant 
services that ensure close contact with individual users is important in order to identify 
problems at an earlier stage and improve access to the services. People with drug and alcohol 
problems should primarily receive help from the ordinary services, and not from a separate 
care service. Among other things, this means that help measures and benefits shall not be 
registered on the basis of the person in question’s diagnosis, but in a more general manner, for 
example as subsistence or housing benefits. This means that it is not possible to isolate the 
total expenditure on persons with drug or alcohol problems who receive municipal health and 
care services.   
Medical expertise in the drugs and alcohol field shall be strengthened, both in the specialist 
health service and in the municipalities. A medical speciality in addiction medicine will 
therefore be established. The Directorate of Health is assisting the Ministry of Health and 
Care Services in this work, which is being carried out in conjunction with the general review 
of the specialist field that the Directorate of Health is carrying out. 
A white paper called Good quality – safe services (Report No 10 to the Storting (2012–2013) 
was considered by the Storting in 2013, cf. Recommendation No 250 to the Storting (2012–
2013). In line with this, the Directorate of Health will develop a tool for improving the care 
pathway in the municipalities, before and after stays in an institution. The purpose is to 
develop care pathways for patients with drug or alcohol problems that can also be used in 
relation to other user groups and in other fields.  
5 BrukerPlan is a tool that maps the prevalence and characteristics of drug and alcohol problems in Norwegian 
municipalities. 
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The Act relating to municipal health and care services6 requires municipalities and regional 
health authorities/health trusts to enter into agreements on a number of tasks, including 
guidelines for cooperation on admission, discharge, habilitation, rehabilitation and learning 
and coping services. Concrete solutions must be developed locally in cooperation between 
different services and levels. More knowledge is also needed about the housing situation of 
people with drug and alcohol problems. The Directorate of Health has been assigned the task 
of carrying out a survey of the housing situation for different groups of people with drug or 
alcohol problems. The Government will present a new national strategy for social housing 
work in 2014. The strategy will bring together and set targets for public efforts, highlight the 
division of responsibility in social housing work and show what instruments can be used to 
help people at a disadvantage in the housing market.  
The Government will strengthen efforts to ensure that people with mental health problems and 
drug and alcohol problems maintain their connection to the labour market. Experience from 
and efforts made in connection with the National Strategy Plan for Work and Mental Health 
2007–2012 will be continued through the Government’s follow-up plan for work and mental 
health,7 which was presented in September 2013. Among other things, the plan describes 
measures aimed at strengthening cooperation between the health and care sector and the 
Labour and Welfare Administration (NAV). Rapid access to mental health care combined 
with work-related follow-up with a view to participation in the ordinary labour market is an 
important part of this cooperation. Trial schemes involving individual job support and the 
Work Proficiency Follow-up Programme are examples of this type of collaboration. 
‘Quality boost’ in the drugs/alcohol and mental health fields 
Efforts in the drugs and alcohol field in recent years have contributed to more knowledge 
about drug and alcohol problems, but there is a lack of good quality indicators and 
information about the services provided to people with drug and alcohol problems and about 
the use of resources. Competence-raising measures implemented through the escalation plans 
for the drugs/alcohol and mental health fields have been retained and integrated in the 
Government’s competence strategy: Kvalitetsløft rus og psykisk helse (‘A quality boost in the 
drugs/alcohol and mental health fields’). The strategy is intended to ensure the necessary 
expertise in the services offered to people with drug or alcohol problems and people suffering 
from mental illness. The quality boost has three focus areas: 
 
 
6 http://www.lovdata.no/all/nl-20110624-030.html 
7 http://www.psykiskhelse.no/index.asp?id=32171 
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• Competence plan for the drugs/alcohol and mental health fields (recruitment and 
qualification etc.)  
• A better basis for management, knowledge about health challenges and treatment 
• Research, development and knowledge support. 
 
Key measures include: 
• Strengthening continuing and further education  
• Establishing a medical speciality in addiction medicine  
• Facilitating good management.  
 
The Directorate of Health has also established two working groups that are working on 
developing quality indicators in the mental health and drugs/alcohol fields; one for the 
specialist health service and one for the primary health service. The goal is to establish a 
national system of quality indicators for the specialist and primary health services that can 
serve as support for internal quality improvement, health policy management and corporate 
governance.  
The Directorate of Health has signed a three-year contract for the further development and 
implementation of the BrukerPlan tool in all municipalities in the course of 2013.  
Health and care services are priority areas in the Government’s research and innovation work. 
Through the escalation plans for mental health and the drugs and alcohol field, considerable 
efforts have been made to strengthen research and the dissemination of research-based 
knowledge. Research activities have been strengthened through the Norwegian Institute of 
Public Health, the Norwegian Institute for Alcohol and Drug Research (SIRUS), the Research 
Council of Norway’s Programme on Alcohol and Drug Research and Research Programme on 
Mental Health, and the regional health authorities.  
One of the main tasks of the seven regional drug and alcohol competence centres is to 
stimulate the development of preventive measures in the field of drugs and alcohol in the 
municipalities. To some extent, the competence centres also engage in research in areas for 
which they have national responsibility. Dedicated user experience surveys will be introduced 
in connection with interdisciplinary specialist treatment for problem drug and alcohol use 
(IST), and separate key figure reports will be prepared in this field in order to monitor 
developments and to increase knowledge about the users’ own experience of and need for the 
services. 
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Problem drug and alcohol use does not only affect the user. Many children have parents with 
high-risk consumption levels, particularly in relation to alcohol. In order to strengthen efforts 
aimed at family members of people with drug and alcohol problems, two living condition 
surveys focusing on children and adults, respectively, as next-of-kin were initiated in 2013. 
The objective is to gain more knowledge about their experiences, and how they cope with 
everyday life. The results are intended to form the basis for further measures. Both living 
conditions surveys are seen in conjunction with a large-scale survey on ‘children as next-of-
kin’ led by Akershus University Hospital. The final report will be presented in 2014.  
Strategy relating to overdoses  
Norway ranks high on the European statistics for overdoses. The is uncertainty attached to the 
data on which the comparison is based, however, including different interpretations at the 
national level of causes of death. The annual registrations show that the number has decreased 
since 2001, when 405 drug-related deaths were registered in Norway. In 2011, 262 such 
deaths were registered. The figures remain high despite the fact that a number of measures 
have been implemented. Most overdose deaths occur in private, not in public places. Efforts 
to reduce the number of overdose deaths must therefore be made in several arenas. In the 
white paper on drugs and alcohol policy, the Government proposed a national strategy to 
combat overdose deaths. The Storting has endorsed this proposal and adopted a zero-vision 
goal for overdose deaths.8 
On this basis, EUR 1.25 million(NOK 10 million)9 was allocated for 2013 for the 
development of a five-year overdose strategy. The Directorate of Health will complete a 
comprehensive plan setting out several measures. The measures are planned and will be 
implemented in cooperation with user and next-of-kin organisations, municipalities and other 
involved parties. As part of this effort, the Norwegian Centre for Addiction Research 
(SERAF) has been assigned the task of initiating a trial project in Oslo and Bergen that 
involves distributing naloxone nasal spray to users and next-of-kin. SIRUS will carry out a 
follow-up evaluation of the implementation of the strategy. See also Chapter 7. It will include 
such measures as influencing the user culture, among other things by aiming to change the 
method of use of heroin from injection to inhalation in order to reduce the risk of overdoses. 
Smoking also prevents injection-related diseases such as HIV and hepatitis, and injuries 
caused by harmful injection practices. As mentioned, a proposal to amend the Drug Injection 
Rooms Act to permit the inhalation of heroin in injection rooms has been distributed for 
consultation.  
8 Recommendation No 207 to the Storting (2012–2013) 
9 Conversion rate: 1 EUR=NOK 8.00 
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Grant schemes 
A number of different grant schemes have been established in order to facilitate the 
attainment of prioritised goals. The white paper confirms the Government’s goal that the 
municipal sector shall primarily be funded through block grants. It is therefore proposed to 
include most of the current grants for municipal work on the drugs and alcohol field in the 
municipalities’ block grants. A number of targeted grant schemes divided between various 
items will nonetheless continue. 
The grant schemes are intended to stimulate engagement and activity in relation to drugs and 
alcohol policy both nationally and locally, through operating grants and grants for projects 
and activities in pursuit of drug and alcohol policy goals. The schemes are intended to 
promote knowledge-based strategies and democratic work by organisations based on 
voluntary efforts and local involvement, categorised as: The prevention of drug and alcohol-
related problems – to help to limit drug and alcohol use and the harm caused by drugs and 
alcohol. The allocated funding covers reports, evaluations, trial schemes, international 
cooperation, information and awareness-raising work, including the development and 
dissemination of methods for early intervention and mini-interventions. 
Drug and alcohol measures – aimed at stimulating high-quality, coordinated preventive work 
in the municipalities, including work to stimulate drug and alcohol action plans and better 
coordination and utilisation of local resources. The allocation also covers grants for:  
• the establishment and continuation of a system of municipal drugs/alcohol and crime-
prevention coordinators, in cooperation with the Norwegian National Crime 
Prevention Council;  
• operating grants for drug and alcohol policy organisations; 
• project grants for the development of voluntary drug and alcohol prevention projects 
and activity grants for voluntary drug and alcohol prevention measures; 
• grants for the regional drug and alcohol competence centres and their work on 
preventive strategies targeting the municipalities; 
• grants for the ‘doping helpline’; 
• operating grants for the Workplace Advisory Centre for Issues related to Alcohol, 
Drugs and Addictive Gambling in the Workplace (AKAN); 
• grants for drug and alcohol prevention in the workplace; 
• grants for the development and dissemination of knowledge about national public 
health measures; 
• operating grants for Anti-Doping Norway’s work targeting doping as a social problem. 
The grant schemes are administered by the Directorate of Health. 
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Other grant schemes  
Continuing and further education – aimed at raising the level of expertise in drug and alcohol 
problems among doctors and other health personnel.  
User and next-of-kin organisations in the drugs and alcohol field shall be strengthened 
through operating grants and grants for information activities. The purpose is to promote 
increased user participation at both the individual and system level, and to contribute to the 
development of meeting places and tools for user participation.  
Municipal work in the drugs and alcohol field 
From 2013, the purpose of the allocation was changed to contributing to competence-raising 
measures and quality development in the drugs and alcohol field and measures aimed at 
improving coordination between municipalities and the specialist health service. The 
allocation will now be used for: 
• The development and testing of coordination models in the drugs and alcohol field 
• Cooperation on patients who are ready to be discharged 
• Stimulus grants for continuing and further education 
• Training in the use of mandatory treatment and coercion. 
The development and testing of coordination models in the drugs and alcohol field was  
established in 2013 in order to contribute to the development and testing of models for 
improved coordination. The scheme is intended to contribute to the development of binding 
organisational cooperation models between municipalities and health trusts/regional health 
authorities, including private and non-profit service providers who have agreements with the 
regional health authorities. 
Cooperation on patients who are ready to be discharged – in order to improve cooperation 
between drug and alcohol institutions in interdisciplinary specialist drug/alcohol treatment 
and the municipalities on patients who are ready to be discharged.  
The regional drugs and alcohol competence centres 
The seven regional drugs and alcohol competence centres are tasked with assisting the 
municipalities and the specialist health service with competence-raising measures and 
professional development related to drug and alcohol prevention work. They provide 
knowledge support to the services, and, in cooperation with the county governors, they initiate 
various competence-raising measures and help to ensure that the municipalities apply 
knowledge that is based on research and good practice. In 2013, a total of EUR 17.4 million 
(NOK 139 million) was allocated to the centres. The centres provide further and continuing 
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education, courses to raise the level of basic knowledge among e.g. NAV employees, and 
especially adapted courses for groups of employees in individual municipalities. The 
municipalities are given guidance on how to develop drug and alcohol policy action plans and 
competence-raising measures for employees in municipal services and the specialist health 
service. The implementation of national guides and professional guidelines in the drugs and 
alcohol field is part of this work. Regional interdisciplinary drug and alcohol forums have 
been established in most counties.  
The centres also perform national functions in the following areas of expertise: gambling 
addiction; dual diagnosis; outreach social work among young people; ethnic minorities and 
drugs/alcohol; pregnant women with drug/alcohol dependency and families with small 
children; gender and drugs/alcohol; parents’ role in drug and alcohol prevention work; 
drugs/alcohol and the workplace; drug and alcohol problems in families with children; drug 
and alcohol problems relating to youth and young adults, with the emphasis on early 
intervention; drug and alcohol prevention work based in schools.  
 
1.3 Economic analysis 
Various attempts have been made to calculate the social costs of the use of drugs in general, 
and alcohol in particular. However, there are extensive methodological challenges relating to 
such calculations, and the results vary greatly depending on which calculation model is used. 
The figures are therefore too uncertain to be useful. Some work is under way that may 
contribute to better estimates and overviews, however. For the time being, the only thing that 
is certain is that drugs and alcohol and their use have considerable costs, both in monetary 
terms and in terms of human costs. Nor is it possible to isolate the costs of prevention, 
treatment, care or law enforcement. In 2012, the specialist health service allocated EUR 480 
mill (NOK 3,840 billion) for interdisciplinary specialist treatment for drug and alcohol 
problems.  
Direct allocations for the drugs and alcohol field have increased by approximately EUR 145.6 
million (NOK 1.165 million) since 2005. In addition, the municipal sector has received a 
significant financial ‘boost’ that has also benefited the drugs and alcohol field. This has made 
it possible to develop preventive and help measures for persons with drug and alcohol 
problems.  
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2 Drug use in the general population and specific 
target groups 
 
2.1 Drug use in the general population 
SIRUS conducted surveys of the Norwegian population’s use of alcohol and drugs from 1968. 
The surveys have normally been carried out every five years. The drugs questionnaire was 
part of a more comprehensive survey that was mainly concerned with alcohol consumption 
and attitudes to alcohol policy issues. Data collection in these surveys was carried out in the 
form of face-to-face interviews. The data concerning drugs were later linked to the other data 
from the interview survey. The last survey using this method was carried out in autumn 2009, 
and the data were presented in the National Report for 2010, Chapter 2. However, one should 
be aware that prevalence figures from these surveys are probably biased due to a problematic 
sampling procedure and declining response rates. In the 2009 survey, the response rate was as 
low as 18 per cent.  
New population survey in 2012 
As a result of declining response rates in previous surveys, SIRUS entered into acollaboration 
with Statistics Norway on an annual national population survey using a different approach in 
order to measure the use of tobacco/moist snuff, alcohol, drugs and medicines. This approach 
involves drawing a representative sample from the population register and conducting phone 
interviews with the subjects after they have received an information letter in advance. The 
sample is drawn from the 16–79 age group, with oversampling from the 16–30 age group. In 
order to adapt the survey to the classification that the EMCDDA uses, only respondents in the 
16–64 age group are asked about the use of illegal substances. An error was made in the 2012 
survey, however, so that only those who stated that they had ever used hash/marijuana were 
asked about other illegal substances. This means that no data are available for 2012 on other 
drugs than cannabis.  
The 2012 survey had a response rate of 53 per cent and consisted of 1,947 respondents, 1,668 
of whom were in the 16–64 age group. The results were weighted for age, gender, educational 
level and region. Since the approach and method differ, the data in the old and new series of 
population surveys are not directly comparable. We can nevertheless attempt to present some 
of the data.  
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Features from the 2009 survey: 
• The proportion of respondents who answered that they had ever tried cannabis had 
fallen from approximately 16 per cent in 2004 to less than 15 per cent in 2009. The 
fact that lifetime prevalence has fallen during the past five years is somewhat 
surprising given the cumulative nature of the variable. The most likely explanation is 
the low response rate. 
 
In the 2012 survey, approximately 19 per cent reported having ever used cannabis (LTP), 
while 3.4 per cent stated that they had used it during the last 12 months (LYP) and 1.5 per 
cent reported use during the last four weeks (LMP) (Figure 1). Significantly more men than 
women reported having used cannabis for all three time intervals.  
 
Figure 1: Percentage in the 16–64 age group in 2012 who have taken cannabis ever, during the 
last 12 months and during the last 30 days, respectively*  
  
*Net response: 1,668 
 
Source: SIRUS/Statistics Norway  
 
Features from earlier surveys: 
• Lifetime prevalence in the 2004 and 2009 surveys was highest in the 25–34 age group, 
while both the proportion who have taken cannabis during the last year and during the 
last 30 days was highest in the 15–24 age group. What was more surprising is the 
relatively strong decrease from 2004 to 2009 in the proportion who have used 
cannabis during the last 30 days in the under-35 age group. In 2004, it was 4.5 per 
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cent, while in 2009, it had been reduced to 2.1 per cent. Furthermore, last-year 
prevalence also decreased in the 15–34 age group, from a proportion of 9.6 per cent in 
2004 to 7 per cent in 2009.  
This corresponds quite well with the 2012 survey (Figures 2, 3 and 4). Lifetime prevalence 
was higher in the 25–34 age group than in the younger age groups (39.6%), while the 16–24 
age group had by far the highest proportions for both use during the last year (11.7%) and use 
during the last month (5.1%). For the 16–34 age group as a whole, the proportion who 
reported use during the last year, 7.9 per cent, was fairly similar to the proportion in the 2009 
survey. For use during the last month, the number of respondents is low in many of the age 
groups, which means that there may be considerable statistical margins of error.  
Synthetic cannabinoids  
In the 2012 survey, respondents were asked a separate question about the use of synthetic 
cannabinoids. In the 16–30 age group (N=706), nine per cent reported having used one or 
more cannabis products in the last 12 months. In addition, 3 per cent reported having used 
synthetic cannabinoids, but this only accounted for 0.3 per cent of the whole sample. 
 
Figure 2: Percentage in the 16–34 age group in 2012 who have taken cannabis ever, during the 
last 12 months and during the last 30 days, respectively* 
 
*Net response: 620 
 
Source: SIRUS/Statistics Norway  
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Figure 3: Percentage in the 16–24 age group in 2012 who have taken cannabis ever, during the 
last 12 months and during the last 30 days, respectively*  
 
*Net response: 317 
 
Source: SIRUS/Statistics Norway  
 
 
Figure 4: Percentage in the 25–34 age group in 2012 who have taken cannabis ever, during the 
last 12 months and during the last 30 days, respectively*  
 
*Net response: 303 
 
Source: SIRUS/Statistics Norway  
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2.2 New study – Estimation of cocaine consumption in a 
community: a critical comparison of the results arrived at 
by three complimentary techniques 
 
As a range of approaches are now available to estimate the level of drug use in a community, 
the authors of a recently published study (Reid et al., 2012) find it desirable to make a critical 
comparison between results from the different techniques. The paper presents a comparison of 
the results from three methods for estimating the level of cocaine use in the general 
population.  
The comparison applies to a set of regional-scale sample survey questionnaires, a 
representative sample survey on drug use among drivers, and an analysis of the quantity of 
cocaine-related metabolites in sewage.  
Setting: In total, 14,438 participants provided data for a set of regional-scale sample survey 
questionnaires, 2,341 drivers provided oral-fluid samples, and untreated sewage from 570,000 
people was analysed for biomarkers of cocaine use. All data were collected in Oslo.  
Results: 0.70 (0.36–1.03) per cent of drivers tested positive for cocaine use, whichs suggest a 
prevalence that is higher than the figure of 0.22 (0.13–0.30) per cent (per day) derived from 
regional-scale survey questionnaires, but the degree to which cocaine consumption in the 
driver population follows consumption in the general population is unknown. Despite the 
comparatively low prevalence figures, the survey questionnaires did provide estimates of the 
volume of consumption that are comparable with the amount of cocaine-related metabolites in 
sewage. Consumption estimates per user are highlighted as a significant source of uncertainty, 
however, as little or no data are available on the quantities consumed by individuals and much 
of the existing data is contradictory.  
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3  Prevention 
 
Introduction 
Norway’s preventive work is based on a long-term, continuous perspective. For more than a 
decade, prevention has been rooted in the Government’s action plans (See NR 2011 and 
2012, Chapters 1 and 3). The white paper ‘Se meg! En helhetlig rusmiddelpolitikk’ (‘See me! 
A comprehensive drugs and alcohol policy’: Report No 30 to the Storting (2011–2012) 
emphasises the prevention of drug and alcohol problems as an important priority area from a 
public health perspective. See Chapter 1.1 for a more detailed description.  
A new Public Health Act entered into force on 14 February 2013. The Act is intended to 
contribute to society developing in a manner that promotes public health and evens out social 
differences in health. One of the main features of the Act is that responsibility for public 
health work is not limited to the municipal health service. All the municipal services shall 
take part in the work on promoting public health. The Act gives the municipalities greater 
responsibility for prevention and health-promoting work in all areas of society. Drug and 
alcohol prevention work will therefore be a natural, integral part of this work and shall have a 
clear public health perspective. 
The Norwegian Directorate of Health’s task is to contribute to local implementation of 
preventive measures. The seven regional competence centres for the alcohol and drugs field 
are key partners in coordinating and improving local prevention in the municipalities. 
Preventive work that varies in its nature and scope is ongoing in all municipalities. Some of 
the centres have websites in English, e.g.: http://www.borgestadklinikken.no/english. The 
municipalities are responsible for local drug and alcohol prevention work and early intervention, and 
for following up people with drug or alcohol problems at the local level. Since 2011, the county 
councils (elected county-level bodies) have had a statutory responsibility for public health work at the 
regional level. 
 
3.1 Universal prevention 
The prevention paradox means that a small change in many people’s behaviour can have a 
greater impact on public health than a major change in a small group. The use of illegal drugs 
in Norway is a small public health problem compared with the use of alcohol and tobacco, 
however. This raises the question of how the health authorities should address universal drug 
prevention. Research indicates that there is a connection between the use of tobacco at a 
young age and alcohol and drug use. It is therefore reasonable to see tobacco and alcohol 
prevention as universal prevention strategies that also contribute to reducing the use of drugs.  
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At present, the health sector’s drug prevention work primarily targets risk groups and persons 
with incipient problems. These risk factors or incipient problems are not necessarily related to 
drug use alone – high alcohol consumption, mental illness, social problems, problem 
behaviour etc. can also be indications. 
 
3.1.1 Community 
Competence-raising in the municipalities 
Work continues on competence-raising in the municipalities, and the seven regional 
competence centres play an important role in this context. The role of the county governors 
(seminars, counselling, supervision) has also been strengthened. Competence-raising 
measures target key personnel in the municipalities (administrative decision-makers, 
politicians, relevant sector managers, the retail and licensed trades, the police, health 
personnel, local school managers, teachers, parents/guardians and voluntary organisations). 
In order to achieve the goal of better coordination of preventive measures, the municipalities 
have been required to prepare comprehensive drugs and alcohol policy action plans (cf. 
Norwegian legislation relating to alcohol) for several years, and to link preventive work 
relating to drugs and alcohol to other public health work in the municipality. This work 
continues in relation to both drugs and alcohol. The municipalities are required to assess their 
practice in relation to issuing licences for the sale and serving of alcohol as part of the drugs 
and alcohol policy.  
Several other laws also assign the municipalities responsibility for tasks in the drugs and 
alcohol field. Based on the intentions of the acts and the municipalities’ own needs, the 
municipalities are encouraged to pursue a coherent drugs and alcohol policy, and to have a 
plan for this work, in which drugs and alcohol policy challenges are seen in conjunction with 
licensing arrangements and other preventive efforts as well as rehabilitation. The Directorate 
of Health, the regional competence centres and the county governors assist the municipalities 
in the development and implementation of such plans.  
Ungdata: New tool for the municipalities 
Ungdata is a standardised system for local questionnaire surveys on various aspects of young 
people’s lives, including the use of drugs, alcohol and tobacco. The surveys are adapted to 
pupils in lower and upper secondary school. The questionnaire consists of a compulsory basic 
module that is used in all the surveys and a set of optional, pre-defined questions from which 
the municipalities can choose. They can also add their own questions. The surveys are carried 
out during school hours and are conducted electronically.  
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The municipalities’ control of the sale and serving of alcohol 
In accordance with the Public Health Act, the Directorate of Health has taken a clearer stance 
on how the municipalities’ drugs and alcohol policy should be designed. Among other things, 
this applies to the control of sales and serving activities in order to reduce the harmful effects 
of alcohol.  
Norwegian alcohol legislation contains many provisions aimed at limiting availability, 
including a licensing requirement, age limits for the sale and serving of alcohol, sales and 
licensing hours, and restrictions on serving/selling alcohol to people who are clearly under the 
influence of alcohol or drugs. It is the municipalities’ responsibility to enforce the law in their 
area. Surveys still show that municipal control of the sale and serving of alcohol is not good 
enough. In December 2012, the Directorate of Health launched a guide to inspections aimed 
at municipalities and sales and licensed premises inspectors. One of the goals is to establish a 
national norm/standard for good inspections and procedures.  
Responsible handling of alcohol 
The municipalities’ use of the provisions of the Alcohol Act is considered to be one of the 
most important means of limiting alcohol-related harm. A big initiative aimed at responsible 
handling of alcohol has been launched in order to strengthen the local administration of the 
Alcohol Act. The initiative includes: 
• Competence-raising in the municipalities 
• Developing guides and material, including a guide for municipal supervision of 
licences for the sale and serving of alcohol 
• Materials and tools for the licensed trade 
• Encouraging cooperation between the local authorities, the police and the industry, 
based on a Swedish model (‘Ansvarsfull alkoholservering’ – ‘Responsible serving of 
alcohol’) 
• Information work and campaigns 
• Improved documentation and knowledge development 
• A national alcohol conference  
• A set of preventive measures relating to the Alcohol Act  
• Interest group for municipal case officers  
 
28 | The Drug Situation in Norway 2013 
3.1.2 Family 
Parents’ role in drug prevention 
Work that supports parents is one of the most important areas in relation to children and 
young people at all levels of drug and alcohol prevention work. One of the regional 
competence centres (the competence centre in Bergen in Western Norway) is continuing work 
on its five-year plan, focusing on the role of parents as its area of expertise. One of the 
measures is to develop guidelines for parental support to prevent young people from using 
alcohol at an early age. The nationwide campaign www.settegrenser.no, which is part of the 
parent-oriented efforts, has been ongoing since 2005/2006.  
 
3.1.3 School 
Schools are an important arena for drug and alcohol prevention work in the broadest sense. A 
good learning environment, cooperation between the home and school, adapted tuition, social 
competence, methods that activate pupils, authoritative classroom leadership and the school 
health service are key elements in this work. An electronic guide for drug prevention in 
schools, based on these principles, was published in early summer 2012 in cooperation with 
the educational authorities. 
 
3.2 Selective prevention – at-risk groups and settings  
The guide ‘From Concern to Action – A guide to early intervention in the alcohol and drug 
field’, which was published in 2009 in collaboration with three other directorates, is part of a 
long-term early intervention effort in the drugs and alcohol field (See NR 2010, Chapter 
3.1.1.). The guide is now well known in the municipalities, and it has been updated. 
The training programme Early prevention, drugs and alcohol and violence in close 
relationships has been continued. An English summary of the report, published in autumn 
2012, is now available at: 
http://www.sirus.no/filestore/Import_vedlegg/Vedlegg_publikasjon/sirusrap.5.12.pdf 
Several projects relating to dropping-out from school are ongoing all over the country. Some 
of the main objectives are: to develop and implement procedures for registering and following 
up pupils who play truant, to raise the level of competence among staff who work closely with 
pupils, and to strengthen cooperation between the home and school. 
Low-threshold services and outreach activities have been strengthened, for example through 
grant schemes for municipal drugs and alcohol work and grants for other measures (Chapter 
1.2).  
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3.2.1 At-risk groups 
A number of methodology development projects have been initiated in different 
municipalities. The projects largely target at-risk young people aged between 11 and 23, 
children of problem drug and alcohol users and parents with mental illness, and early 
intervention in relation to pregnant women and parents of infants and small children. Work is 
under way on summarising the results of the projects, which will be used to identify ‘best 
practice’.  
The ‘Ut av tåka’ (Out of the fog) quit smoking hash courses  
The initially Oslo-based measure was described in NR 2011 and 2012, Chapter 3. It is based 
on intersectorial cooperation, and on the systematic development of local competence and 
methods based on experience from Sweden and Denmark. There have been two target groups: 
youth aged between 15 and 25 who are motivated to stop using cannabis, and first-line staff in 
the city wards whose day-to-day work involves contact with these young people. The 
initiative has helped professionals to develop their competence and enabled them to offer 
young people in their ward an opportunity to quit smoking hash, both through groups and 
individually.  
A lot of work has been invested in the training of personnel and cooperation with city wards 
in Oslo in order to enable them, in the longer term, to run these courses on their own and offer 
them to young people in their ward. Some city wards have run groups in cooperation with the 
‘Out of the fog’ project. The wards are also given guidance, and there is cooperation on 
follow-up. The project is also working on making the quit-smoking- hash course and method 
better known and on developing the methodology. A total of 98 persons were followed up 
through the project in 2012, compared with 64 in 2011. In 2013, the project as such was 
discontinued, and a permanent hash smoking cessation service was established that is now 
available to people of all ages, including OST clients. A team of three expert consultants is 
working on getting people to stop using hash in Oslo. Such courses probably reach young 
people who would not otherwise seek help for their drug problems. Increased focus on and 
knowledge about cannabis in the help services will also help more young people to seek help 
for their problems at an earlier stage.  
Similar courses aimed at weaning people off cannabis are also held in other Norwegian cities. 
In Norway, the municipality of Kristiansand is leading the way in the work of getting people 
to stop smoking hash, and the local authority has also established a course on (the prevention 
and treatment of problem use of) cannabis (5 credits) in collaboration with the University of 
Agder. Link: www.hasjavvenning.no 
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Report on the use of khat in Norway 
A recent summary of existing knowledge about khat and health (Ali and Kaur, 2013) shows 
that not much research has been done on the use of khat in Norway and that we know little 
about how large a proportion of the population use khat. A prevalence survey has been carried 
out (Gundersen, 2006). The survey showed that the use and sale of khat is concentrated in 
central parts of Oslo. About 250 people buy and use khat every day in various cafes in the 
Grønland area (editor’s comment: a city ward with a large immigrant population). 
Approximately another 250 people buy and use khat in the Greater Oslo region. If we include 
people from other towns and cities, the estimate is 1,400 persons.  
Those who use khat in Norway are mostly middle-aged men from East Africa and the Middle 
East. It is most prevalent among Somalis. Very few young people use khat. The report shows 
that people who use large quantities of khat can be doubly marginalised in the sense that they 
are on the outside of both mainstream society and their own immigrant communities. They are 
often unemployed, have family and financial problems, struggle with traumas and have an 
uncertain immigration status. In general, we can say they are not very well integrated in 
Norwegian society. Khat is chewed in social contexts, and khat milieus can therefore be the 
result of a quest for security in a society where one feels alienated. The report (Ali and Kaur, 
2013) also shows that the health services know little about khat and khat use. The services do 
not know enough about what symptoms to look for, and many khat users are in a marginalised 
group that has little or no contact with the health services. 
 
3.2.2 At-risk families 
Early intervention 
The work on early intervention continues unabated. The focus has primarily been on raising 
competence in early identification and intervention among staff who come into contact with 
at-risk children and young people, as well as on stimulating increased use of screening tools 
and mini-interventions by staff who come into contact with pregnant women, their partners 
and parents of small children. In relation to adults, the work is intended to help to ensure that 
help services/treatment measures are instigated early enough so that the use of alcohol or 
drugs does not develop into problem use or addiction. All the country’s seven drug and 
alcohol competence centres are working on developing methods for identifying target groups 
in need of measures. The website www.tidligintervensjon.no offers concrete tools that the 
different services can use to discover drug-related problems and follow them up.  
Self-help programmes/websites 
There are several digital self-help programmes aimed at people who wish to change their use 
of or addiction to alcohol, cocaine or cannabis. The programmes are freely available on the 
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internet. Self-help programmes are aimed at people with mild to moderate drug or alcohol 
problems, who live in stable housing and have contact with friends, relatives or colleagues. 
The course/self-help is not suitable for people with a long history of problem drug or alcohol 
use. 
Links: The Bergen Clinics Foundation/ the Bergen Drug and Alcohol Addiction Service 
Competence Centre: Online self-help programmes, alcohol, cannabis and cocaine. 
http://www.bergenclinics.no/index.asp?strUrl=1001996i&topExpand=&subExpand 
AKAN’s Balance, Alcohol: 
https://program.changetech.no/ChangeTech.html?Mode=Trial&P=H8V8X8&C=HJ04HX 
The guide ‘From Concern to Action’ is being implemented in an increasing number of 
municipalities. Link: http://www.helsedirektoratet.no/vp/multimedia/archive/00334/IS- 
1742_Engelsk_Eng_334559a.pdf 
 The Norwegian Electronic Health Library runs a website on behalf of the Directorate of 
Health and the Directorate for Children, Youth and Family Affairs: Screening and mapping 
tools for use in work with parents, pregnant women and children of parents with mental 
health problems and/or drug or alcohol problems The page is used by many different 
professions involved in early intervention work. 
Link: http://www.helsebiblioteket.no/microsite/Kartleggingsverktøy  
  
32 | The Drug Situation in Norway 2013 
4 Problem drug use 
 
4.1 Prevalence and incidence estimates of problem drug use 
 
Definitions  
The EMCDDA defines problem use as ‘Injecting use of drugs or prolonged/regular use of 
opiates, cocaine and/or amphetamines’. ‘Opioids’ is used as a generic term for natural opiates 
(such as opium, Dolcontin), semi-synthetic opiates (heroin) and synthetic opioids (such as 
methadone, buprenorphine). This means that everyone undergoing opioid substitution 
treatment (OST) who is prescribed methadone or Subutex is a problem user according to the 
EMCDDA’s definition. Including such groups can appear strange in Norway, where the 
intention of OST is to get people who have used heroin for a prolonged period to stop using 
illegal drugs. 
In the Norwegian context, however, it might nevertheless be natural to regard a subgroup of 
patients in OST as problem users. Around 9–10 per cent of OST patients report having used 
morphine substances in addition to OST medication during the last 30 days, and 15–16 per 
cent have been found to use stimulants (Chapter 5.3.2). The proportion who have used such 
drugs in the space of a whole year will be higher. In addition, some people move in and out of 
OST and may thus have periods of heroin use before, between or after treatment periods 
during the survey year (Waal et al. 2013).  
In addition to the general definition of problem use, the EMCDDA also uses two underlying 
definitions: injecting drug users and problem users of opioids or heroin. In Norway, we 
primarily have estimates for the group that injects drugs, but the number of problem users of 
heroin in the period 2000 to 2008 has also been estimated (see NR 2009 Chapter 4.2.1 and 
Bretteville-Jensen & Amundsen, 2009). Estimates of users and problem users of cocaine were 
published in the national report for 2011, Chapter 4.1. Work is being done to calculate how 
many problem users we have according to the general definition.  
Estimates of the number of injecting drug users have been revised from and including 2013. 
The mortality multiplier method is still used. It estimates the number of injecting drug users 
by dividing the number of drug-related deaths by the likelihood of dying of a drug-related 
diagnosis (ref.). Previously, there have been two sources of information about such deaths: the 
National Crime Investigation Service (Kripos) and the Cause of Death Registry. The last year 
Kripos published such figures was in 2009. Calculations of the number of injecting drug users 
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must therefore be adapted to data on drug-related deaths pursuant to the EMCDDA’s 
definition.  
The new calculation takes into consideration the fact that some of those who die are not 
necessarily problem drug users according to the EMCDDA’s definition. Recreational users of 
drugs, especially heroin, or users of legal medicinal drugs that contain opioids are examples 
of people who can take a fatal overdose, but who do not fall under the definition of general 
problem use. When calculating the number of injecting drug users, account must also be taken 
of the fact that not all deaths that fall under the EMCDDA’s definition concern injecting drug 
users. The Cause of Death Registry does not record whether a person has injection marks, 
although it is recorded in the post-mortem report. The proportion of injecting drug users 
among the total number of drug-related deaths has therefore been calculated with the help of 
other information in addition to data from the Cause of Death Registry. The method is 
described in Amundsen (2013). 
 
4.2 Prevalence and incidence estimates of problem drug use 
 
Estimates of the number of injecting drug users in Norway 
Figure 5 shows estimates of the number of injecting users in Norway, calculated using the 
revised mortality multiplier. The number of injecting drug users in 2011 was estimated to be 
between 7,300 and 10,300. The average for previously published estimates is also shown. The 
average value is between the lower and upper limit for the new calculation method. Previous 
national reports have shown that the number of injecting users in Norway increased from the 
1970s until 2001, followed by a reduction until 2003. The figure has since remained stable. 
The most recent figures from the Cause of Death Registry are from 2011.  
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Figure 5: Intervals for the number of injecting users in Norway 2004–2011 using the revised 
method and average values for previously published estimates 2004–2009  
 
Source: SIRUS 
 
 
The figures include all injecting drug use. Heroin is still the most common drug injected, but, 
for an increasing number, amphetamine is becoming the main drug injected. The proportion 
of injecting drug users in Oslo who had primarily injected amphetamine during the past 
month was approximately 20 per cent in 2002–2004. In 2008–2010, the corresponding figure 
was approximately 35 per cent (unpublished results from a study conducted among injecting 
drug users in Oslo, Bretteville-Jensen, SIRUS). It has also become more common to inject 
heroin and amphetamine at the same time. 
New injecting drug users in Oslo over time (incidence) 
With the help of interviews of injecting drug users, the number of new injection drug users in 
Oslo has been calculated for the period 1985 to 2008 (Amundsen et al., 2013). The number of 
new users fell from approximately 350 in 1985 to approximately 140 in 2008 (a decrease of 
60 %). The reduction was greatest during the periods 1985–1992 and 2003–2008.  
 
4.3 Data on problem drug users from non-treatment sources 
A total of 413 persons were interviewed in a study (Amundsen and Reid, 2013) that measured 
the quantities of amphetamines, cocaine and heroin consumed by marginalised drug users, 
using a multi-city questionnaire survey design. Eligible respondents were persons aged 18 
years and over who had used amphetamines, cocaine, heroin or other opioids during the last 
12 months in Oslo, Arendal and Tromsø. Respondents were recruited through contacts 
established via local caregivers working in services for marginalised drug users, both not-for-
profit organisations and public services. 
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Forty per cent reported heroin as the drug most frequently used over the last 12 months, 
followed by 31 per cent reporting amphetamines and one per cent reporting cocaine. Others 
(28%) reported opioids as their most commonly used drug in the last 12 months. Twenty four 
per cent were women, 12 per cent were under 30 years of age, and 25 per cent were more than 
50 years old. Among users of amphetamines, 38 per cent reported more than 20 days of use 
over the last 30 days. Comparable figures were 2 per cent for cocaine and 43 per cent for 
heroin. 
In the same study, the proportion who had injected drugs in the last year varied from 73 per 
cent in the smallest town (Arendal), to 82 per cent in Oslo and 86 per cent in the medium-
sized city (Tromsø). Estimating a nationwide proportion based on the results from these three 
towns and cities is of course difficult. However, by assuming that the proportion of injecting 
users in the total group of problem users decreases with the size of the municipality, the 
weighted average of the proportion of problem users who inject drugs could be 72 per cent for 
the country as a whole. We can use this figure to estimate the total number of problem users 
in accordance with the EMCDDA’s definition. If the number of injecting users make up 72 
per cent of the total number of problem users, we can multiply the number of injecting users 
by 1.4 (= 1/0.72) in order to arrive at an estimate of the total number of problem users. This 
puts the number of problem users at between 10,200 and 14,400. The estimate of the number 
of problem users may be somewhat low, however, because, according to the EMCDDA’s 
current definition, it should include all OST patients. Due to the recruitment method used in 
the surveys conducted in the three towns/cities, persons receiving opioid substitution 
treatment (OST) are likely to have been somewhat underrepresented in the sample.  
 
4.4 Intensive, frequent, long-term and other problematic 
forms of use 
In the 2012 population survey (Chapter 2), between 0.5 and 2 per cent of the 16–40 age group 
reported having used cannabis more than 50 times in the last 12 months. This indicates that a 
relatively large group of people used cannabis once a week or more. Although the size of this 
group is unclear, there is reason to believe that there is a group of people in Norway who may 
experience considerable problems relating to their use of cannabis. This is also reflected in the 
fact that 1,711 of those who started treatment for drug or alcohol problems in the specialist 
health service in 2012 reported cannabis as their main problem, cf. Chapter 5 on treatment. 
However, there are no studies to clarify how big the group is and who these people are.  
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5 Drug-related treatment: treatment demand and 
treatment availability  
 
5.1 General description of systems  
The treatment systems and its organisation were described in more detail in NR 2011 Chapter 
5.3. Residential treatment was thoroughly dealt with in a selected issue in NR 2012. With the 
exception of OST, the treatment systems have not changed in recent years.  
The state has overriding responsibility for providing necessary specialist health services for 
the public. This also applies to people with drug or alcohol problems. The Administrative 
Alcohol and Drug Reform of 2004 stipulates that the four regional health authorities shall 
provide outpatient and in-patient interdisciplinary specialised treatment, either through their 
own health trusts or through private partners. In-patient treatment includes services for 
detoxification, stabilisation and assessment, short and long-term in-patient treatment. 
Interdisciplinary specialised treatment also covers treatment with methadone or Subutex, in 
addition to other treatment and follow-up services.  
The Norwegian OST programme was established in 1998. It was run by 14 centres in the four 
health regions until 2010. Special guidelines were introduced from 1 January 2010, which 
emphasised, among other things, that OST should be integrated in the ordinary specialist 
health service (see NR 2010 Chapter 11). OST centres are no longer a separate type of 
measure, and the system of special decision-making powers has been discontinued. The four 
regional health authorities have established assessment units that make an overall assessment 
of what type of treatment is needed for the person in question, whether he/she needs OST or 
non-medical treatment.  
The municipalities’ overall effort to provide help targets the general population, at-risk groups 
and those who already have drug or alcohol problems, and their surroundings. The services 
can include mental and somatic health services, outreach ambulant services/community-based 
teams, services for next-of-kin, low-threshold services, assessment and referral to treatment, 
as well as follow-up during and after treatment in the specialist health service or in prison. 
The full range of local services for persons with drug or alcohol problems includes services 
from a number of sectors. Key service providers are the Norwegian Labour and Welfare 
Service (NAV), GPs, health stations, the school health service, child welfare services, home-
based care services, nursing homes, psychologists, municipal drugs/alcohol and mental health 
units, residential services and low-threshold health services. 
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The NAV offices are contact points for the local labour and welfare administration. They 
offer a broad range of work-related measures and municipal social services. As a minimum, 
the NAV offices shall provide advice and guidance, social security benefits, qualification 
programmes and temporary housing. The municipalities are free to assign responsibility for 
other municipal tasks to the NAV offices (Ministry of Health and Care Services, 2012). 
Challenges 
In the white paper on alcohol and drug policy of June 2012, the Government stated that 
‘extensive efforts have been invested in the drugs and alcohol field in recent years, both in the 
municipalities and in the specialist health service. However, user organisations and experts 
point out that the services must be involved at an earlier stage and that the availability of the 
services must be improved. Lack of coordination is another important challenge. Many clients 
and patients experience problems when responsibility for further follow-up is transferred to 
new services. This is a problem both within and between sectors and levels.  
Evaluations indicate that coordination between the administrative levels, the specialised and 
the municipal services is not good enough. The services are perceived as fragmented, often 
with long waiting times for treatment. The time spent in in-patient treatment has also been 
reduced compared with what used to be the norm. Following a stay in the specialist health 
service, patients shall be followed up by their municipality. The transition from state to 
municipal services often leads to interruption of treatment, which results in a poorer health 
situation for the users. Cooperation between the first and second-line services is often based 
on personal relations, not the structure of the treatment chain. 
There is a need to clarify the individual services’ tasks and responsibilities. The biggest 
challenges for people with drug/alcohol dependency who need extensive help are to get 
sufficient care for somatic and mental illness, a lack of suitable housing and coping with their 
daily life and living conditions. Other challenges include a lack of participation in meaningful 
activities, work and a social network.’ 
 
5.2 New research – cohort study of drug users in treatment 
SIRUS has carried out a ten-year prospective cohort study of drug users in treatment 
(Lauritzen, Ravndal and Larsson, 2012). A total of 481 clients recruited from 20 treatment 
facilities were interviewed upon admission to treatment in 1998/1999 and at four follow-up 
sessions: one, two, seven and ten years after inclusion. The facilities were categorised in four 
groups: communal youth facilities, psychiatry youth teams, residential units for adults and 
opioid substitution treatment (OST). The research questions were as follows: 
1) What were the life situations and problems of a selection of 481 problem drug users 
when admitted to treatment? 
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2) How were treatment measures used within the ten-year period?  
3) What changes in life situations and problems can be described? 
The instruments used were: the European Addiction Severity Index (EuropASI), the Hopkins 
Symptom Checklist-25 (SCL-25), the Millon Clinical Multiaxial Inventory-II (MCMI-II) and 
the Childhood Trauma Questionnaire (CTQ). 
The participation rate was high, 91 per cent and 89 per cent, respectively, for the first two 
follow-up interviews after one and two years, and 85 per cent and 77 per cent after seven and 
ten years. The cumulative percentages of deaths were two per cent and four per cent at the 
first and second interviews, and 12 per cent and 15 per cent at the last interviews.  
Drug users in treatment have varied backgrounds, substance use and functionality levels. The 
study nevertheless highlights certain themes in the description of the cohort at the time of 
inclusion. The overall problem characteristics could thus pose challenges in relation to 
preventive strategies and future treatment initiatives. The findings confirm the need for 
evaluation and treatment of alcohol and drug problems in a family and generational 
perspective, further research on the complex weave of genetics, environmental influences and 
life events, and a continuation of an action plan initiated for children as next-of-kin. To help 
to prevent problems from developing, the report includes reflections on the need to raise 
competence in different arenas that work with children.  
Between 60 and 70 per cent reported major learning difficulties and/or behavioural problems 
in primary/lower secondary school. The level of education among drug users in treatment was 
generally low, and the majority had very limited work experience later in life. Various models 
to strengthen multidisciplinary competence in, or in close collaboration with, the school 
system therefore need to be discussed. Daily life before admission to treatment was generally 
characterised by serious substance use, injecting drugs and a high risk of overdosing, 
insufficient social functioning outside drug circles, as well as excessive crime.  
The description of changes applies to the entire selection and the four recruitment groups.  
The proportion of HCV infections was generally high. With the exception of those who died, 
the changes described appear to have several positive elements. A substantial reduction in the 
use of drugs and participation in criminal activity was noted after ten years. The most 
significant reduction was seen in the proportion of heroin users, and a considerable decrease 
was found in injecting heroin/drugs and in non-fatal overdoses. This can primarily be linked 
to an increase in daily use of OST medication. The proportion who used cannabis and 
sedatives/hypnotics dropped significantly within the first two years of follow-up, but the 
decrease was not as long-lasting and steady as for heroin use. Multiple crime decreased 
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significantly. The sale of drugs and robbery/theft were reduced in particular, and the study 
seems to confirm the strong link between such crime and individual drug problems.  
The proportion who had income from employment increased to about one-third at the time of 
the last observation. A considerably higher proportion of clients were on disability benefits 
than at the time of inclusion. As a result of more stable income sources, benefits from social 
welfare services were strongly reduced. Another positive result involved improvements in 
housing. Loneliness seemed to be a persistent problem, however.  
The group suffered enduring mental disorders. Although improvements were reported during 
the index treatment and at the two first follow-ups, the clients tended to suffer from recurring 
anxiety, depression and a considerable degree of cognitive difficulties. Similar troubles were 
found as regards relationship problems and personality disorders. The study confirms that 
there are significant challenges in relation to the prevention and treatment of psychiatric 
disorders. A large proportion of persons entering treatment for drug abuse seem to require 
comprehensive assistance for years. The index treatment had often not been their initial 
treatment, and combinations of treatment facilities were used in the course of the observation 
period.  
In sum, the study shows substantial, positive changes and thereby gives grounds for cautious 
optimism regarding the prospect of problem drug users changing their behaviour over time. A 
crucial challenge involves helping the many who have reduced or quit their illegal drug use, 
but live on the fringe of society.  
 
5.3 Treatment admission  
 
5.3.1 Data from the Norwegian Patient Register  
The Norwegian Patient Register (NPR) is authorised by the regulations of 2009 to collect 
personally identifiable information about patients in the interdisciplinary specialist health 
service. Patients are identified by a unique number across centres.  
From 2010, it became possible to retrieve the number of patients with a drug problem who 
started in-patient or outpatient treatment in the year in question, as well as some information 
about these patients. The individual data are aggregated and reported to the EMCDDA . So 
far, only treatment started during a calendar year can be reported, without knowing whether 
this is first-time treatment or whether the patient has undergone treatment before.  
 
40 | The Drug Situation in Norway 2013 
According to NPR, a total of 16,778 patients received treatment during the 2012 calendar year 
for drug problems as their primary condition. Of these, 69 per cent were men and 31 per cent 
women. The number includes patients in both in-patient and outpatient treatment, and the 
sample is based on ICD-10 F codes. The biggest group (39%) had problems related to the use 
of opioids as their primary diagnosis. The second biggest diagnosis category was multiple 
drug use at 22 per cent, followed by cannabis at 19 per cent and stimulants at 12 per cent.  
As for those who started treatment for drug-related problems in 2012, reports were submitted 
from 146 units concerning a total of 8,891 patients (2011: 8,817 patients from 159 units), 
3,691 in in-patient and 5,200 in outpatient treatment, including OST. Comparative figures for 
2011 were 3,921 and 4,896. Around 69 per cent of patients starting treatment were men. The 
average age of patients in in-patient treatment was 34 years for men and 36 years for women, 
fairly similar to patients in outpatient treatment (men: 34 years, women: 35 years).  
More than a quarter – 27 per cent – of the patients entering treatment in 2012 had multiple 
drug use as their primary diagnosis (F19). Problems with opioids were the most frequently 
reported diagnosis in both outpatient and in-patient treatment where the primary drug was 
identified. The second most frequent diagnosis was the use of stimulants for patients in 
residential treatment and cannabis upon admission to outpatient treatment. The latter 
accounted for as many as 31 per cent of the patients where the primary drug was identified. It 
is also notable that the proportion with cannabis as their primary drug upon admission to in-
patient treatment had increased to 18 per cent, while it was 11 per cent in 2011. 
 
5.3.2 About patients in OST  
At the end of 2012, there were a total of 7,038 patients in OST (SERAF, 2013), an increase of 
384 from 2011. In previous years, the number of patients has increased steadily by 
approximately 500, while there are now signs that growth is slowing down.  
Admissions 
The number of admissions to OST in 2012 was 823, a decline of 308 from 2011. It was 
especially the number of re-admissions that decreased as a result of changes in the registration 
practice on the transition to a new electronic patient record system. At the end of 2012, 125 
persons were waiting to be admitted for treatment, seven more than the year before.  
Discharges 
The number of discharged patients from OST in 2012 was 409, lower than in previous years 
(487 in 2011). Discharges now represent less than six per cent of all patients in treatment. In 
2011, ten per cent of patients completed their treatment, while the corresponding figure for 
2010 was nine per cent. This can serve to obscure the fact that the proportion who drop out of 
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treatment during the start-up phase may be significantly higher. Nevertheless, it seems that 
most of those who have settled into treatment continue and stay for a long time. The 
registrations distinguish between discharges as a result of a decision by the responsible 
treatment centre, discharges initiated by the patient him/herself and discharges due to death. 
GPs cannot discontinue the treatment at their own initiative. Discharges resulting from 
decisions take place independently of or against the patient’s wishes. Until last year, the 
proportion who were discharged as a result of a decision – i.e. potentially against their will – 
declined strongly, which is in line with the new guidelines. While 39 patients (8% of 
discharges) were discharged as a result of a decision in 2011 (?), the number in 2012 was 65 
(16%). The main reason for terminating treatment is that the patients themselves leave 
treatment. These patients stop showing up or state that they no longer wish to continue the 
treatment. Some patients specifically request other types of treatment or wish to stop using 
morphine substances.  
The number of deaths among OST patients in 2012 was 84. As shown in Table 1, this 
represents 1.2 per cent of all patients in treatment. There appears to have been a slight 
increase from 2006, but the change is small and the two preceding years have seen a reduction 
in relation to the number of patients in treatment. The number of older patients in treatment is 
also increasing, and many of them have various chronic illnesses.  
Table 1: Annual occurrence of deaths during treatment in the OST programme 2002–2012. 
Number and converted in proportion to the number of patients in OST (deaths per 100 patient-
years)  
Year  2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Norway  26 31 21 30 15 32 39 63 54 54 84 
% of all patients in 
 treatment/year  1.5 1.4 0.8 0.9 0.4 0.8 0.8 1.3 0.9 0.8 1.2 
 
Source: The Norwegian Centre for Addiction Research – SERAF 
 
The status survey for 2012  
Data about clients’ current situation, such as health and social conditions and functional level, 
psychosocial treatment, crime and drug and alcohol use, are reported annually in the form of 
status surveys. A total of 5,852 forms (of 6,640 patients in treatment) were completed for 
2012, 78 per cent of all patients in treatment in 2012 (7,489 persons). The average age of 
clients (for whom a form has been completed) was around 42, and the proportion of women 
was nearly 30 per cent. The average age and the gender distribution have been more or less 
unchanged in recent years. A total of 141 patients (2.5%) were in the 21–25 age group, and 
only one was under 21. Although the lower age limit for admissions has been abolished 
following the introduction of the new guidelines (previously 25 years), this does not appear to 
have affected the average age so far. A total of 53 patients were over the age of 60, which 
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indicates that there will be an increasing number of OST patients in care for the elderly in the 
years ahead.  
The proportion treated with methadone was 44 per cent, while 56 per cent were treated with 
buprenorphine-based medication. About two-thirds have their medication prescribed by their 
GP, and GPs thus play a key role in OST. Just under half the patients get their medication 
from pharmacies.  
Retention and social rehabilitation  
According to the status survey, 95 per cent of the patients were in treatment by the end of 
2012, while 5 per cent had been discharged. The response rate was 80 per cent, however, and 
the drop-out rate is probably highest among those who had been discharged at the time the 
survey was conducted (for whom no status form has been submitted). A better measure of 
retention is the proportion in treatment at the end of the year compared with the total number 
in treatment at the start of the year and the number of new admissions during the year. On this 
basis, the retention rate was 92 per cent, i.e. nine out of ten were in treatment at the end of 
2011.  
Occupational rehabilitation is not showing progress. In 2011, 78 per cent were neither 
working nor in education, while the corresponding proportion in 2012 was 80 per cent. Forty-
one per cent had benefits as their main source of income, most of them disability benefit. The 
proportion who live on temporary social security benefits is low, as is the proportion who are 
financially independent. The proportion who have their own apartment or house is high, 
however. According to the status overview, an average of 75 per cent of patients rented or 
owned their own home. The lowest proportions were found in Oslo (59%) and Bergen (66%). 
To a certain extent, this reflects the fact that the housing market is more difficult in large 
towns and cities.  
Drug use  
The findings on drug use are based on reported use during the last 30 days. A proportion of 9 
per cent reported having used an illegal morphine substance during the past month, 33 per 
cent cannabis and 42 per cent benzodiazepines. Half of those who reported using 
benzodiazepines had been prescribed the drug by a doctor. Sixteen per cent reported using 
stimulants. The figures are largely the same as in 2011, but illegal use of morphine has 
declined. The proportion was 12–13 per cent just a few years ago. The situation was also 
measured by calculating the overall score for frequency of drug use and the severity of 
ongoing use during the past month. Forty-two per cent had not used such substances at all, 
and 19 per cent only sporadically, while 28 per cent reported frequent use. All these findings 
are practically unchanged compared with recent years (SERAF, 2013).  
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA |43 
 
6 Health correlates and consequences 
 
6.1 Drug-related infectious diseases  
 
6.1.1  HIV and Aids 
In 2012, 242 cases of HIV infection were reported to the Norwegian Surveillance System for 
Communicable Diseases (MSIS). Eleven of the cases were among injecting drug users: ten 
men and one woman. The median age was 35 years (28 to 49 years). Eight of the eleven 
injecting drug users who were diagnosed as HIV positive in 2012 were persons of foreign 
origin (mostly Eastern European) who had been infected before arriving in Norway.  
As of 31 December 2012, a total of 596 persons had been diagnosed as HIV positive with 
injecting use as a risk factor. This amounts to 12 per cent of all reported cases of HIV since 
1984. In 154 of the cases, the patient had developed Aids (Table 2). No information is 
available regarding how many of the HIV positive injecting drug users are still alive.  
Table 2: Reporting of HIV infection and Aids, Norway 1984–2012. Percentage of injecting drug 
users by year of diagnosis 
 
 
 
HIV 
total 
HIV injecting 
drug use 
Percentage HIV 
injecting drug use 
Aids 
total 
Aids 
injecting drug 
use 
Percentage Aids 
injecting drug 
use 
 1984–
1999 2,018 442 22% 675 112 17% 
2000 175 7 4% 35 5 14% 
2001 157 8 5% 33 8 24% 
2002 205 16 8% 34 4 12% 
2003 238 13 5% 53 6 11% 
2004 251 15 6% 36 4 11% 
2005 219 20 9% 32 4 13% 
2006 276 7 3% 32 4 13% 
2007 248 13 5% 11 0 0% 
2008 299 12 4% 18 2 11% 
2009 282 11 4% 18 1 6% 
Tabellen fortsetter på neste side 
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2010 258 11 4% 22 3 13% 
2011 268 10 4% 19 0 0% 
2012 242 11 5% 25 1 4% 
Total 5,138 596 12% 1,044 154 15% 
Source: The Norwegian Surveillance System for Communicable Diseases (MSIS); the Norwegian 
Institute of Public Health  
 
 
The incidence of HIV among injecting drug users has for many years remained at a stable, 
low level, with about 10 to 15 cases reported per year. The reason for this is not entirely clear, 
but a high level of testing, great openness regarding HIV status within the drug user 
community, combined with a strong fear of being infected and strong internal justice in the 
milieu, are assumed to be important factors. In addition, many of the sources of infection in 
the milieu have disappeared due to overdose deaths or have been rehabilitated through 
substitution therapy or other forms of rehabilitation. However, the extensive outbreaks of 
hepatitis A and B in the late 1990s and early 2000s, and the high incidence of hepatitis C, 
show that there is still extensive needle sharing among this group. For the last few years, the 
majority of injecting drug users diagnosed with HIV were persons of foreign origin (mostly 
Eastern European) who had been infected before arriving in Norway. 
 
6.1.2 Hepatitis 
During the nationwide outbreak of hepatitis A from 1996 to 2000, 1,360 drug users were 
diagnosed with acute hepatitis A. Since then, only sporadic, individual cases of hepatitis A 
have been reported among injecting drug users. Hepatitis A vaccination has been offered to 
injecting drug users free of charge since 2000.  
In the period 1995–2008, a considerable increase in hepatitis B among drug users nationwide 
was reported to the Norwegian Surveillance System for Communicable Diseases. In 2012, 
seven of a total of 46 reported cases of acute hepatitis B involved injecting drug users. During 
the period 1995–2012, the total number of reported cases of acute hepatitis B infection among 
injecting drug users was 1,976. Hepatitis B vaccination has been offered to injecting drug 
users free of charge since the mid-1980s.  
The monitoring of hepatitis C in Norway was intensified from 1 January 2008. The 
notification criteria were changed so that all laboratory-confirmed cases of hepatitis C must 
now be reported to MSIS. Previously, only acute illness had to be reported, and this resulted 
in a very inadequate overview of the real incidence of the disease in the country. In 2012, 
1,515 cases of hepatitis C (both acute and chronic cases) were reported. In 36 per cent of the 
reported cases, no information was provided about the presumed mode of transmission, but in 
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the cases where the mode of transmission is known, 85 per cent were infected through the use 
of needles. For the time being, data from MSIS cannot distinguish between cases involving 
new infection with hepatitis C and cases where the infection occurred many years ago. It is 
therefore not known whether the number of cases of newly acquired hepatitis C infection has 
declined or increased among drug users in recent years.  
Among OST patients, the status survey for 2012 (see Chapter 5.2.2) shows that 66 per cent of 
the clients were hepatitis C antibody positive, roughly the same proportion as in 2011. This is 
lower than expected, and the explanation is probably that the percentage with unknown status 
was as high as 20 per cent.  
Since 2002, small-scale prevalence surveys have been carried out in connection with needle 
distribution and the drug injection room in Oslo in order to register the prevalence of several 
infectious diseases among injecting drug users. These surveys are the only prevalence surveys 
that are carried out regularly among a sample of drug users in Norway. The 2012 survey 
showed that 62 per cent of the injecting drug users tested had had a hepatitis A infection or 
had been vaccinated against the disease, while 35 per cent had had a hepatitis B infection and 
64 per cent had had a hepatitis C infection. Forty-one per cent had hepatitis B markers, 
indicating that they had been vaccinated against hepatitis B.  
 
6.1.3 Bacterial infections 
In the period 2000–2012, six cases of botulism were reported among injecting drug users. In 
addition, one case of anthrax and one case of Clostridium noyvi were reported among 
injecting drug users in the same period. In recent years, five to ten cases of methicillin-
resistant Staphylococcus aureus (MRSA) have been reported annually among drug users. 
There is insufficient data on the incidence of other bacterial infections among drug users in 
Norway. Tuberculosis is very rare among drug users in Norway.  
 
6.1.4  Risk behaviour 
In connection with the 2012 prevalence study among injecting drug users attending needle 
distribution facilities and the drug injection room in Oslo (see 6.1.2), questions about risk 
behaviour were included as part of the survey. Ninety-one currently injecting drug users 
replied.  
Results: 13 per cent reported having shared used needles and syringes in the last four weeks; 
34 per cent reported having shared used injecting paraphernalia in the last four weeks; 35 per 
cent had taken an HIV test in the 12 months preceding the survey, and 36 per cent had taken 
an HCV antibody test in the 12 months preceding the survey.  
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6.2 Drug-related deaths and mortality of drug users  
 
Methodological considerations 
Until 2010, there were two bodies that registered drug-related deaths in Norway: Statistics 
Norway and Kripos (the National Crime Investigation Service). Kripos based its figures on 
reports from the police districts, while Statistics Norway prepared figures on the basis of 
medical examiners’ post-mortem examination reports and death certificates in accordance 
with the WHO’s ICD 10 codes in a General Mortality Register (GMR). With effect from 
2010, Kripos stopped publishing figures for drug-related deaths. Hence, the 2009 figures were 
the final year of reporting from that source. 
With effect from 1996, Statistics Norway’s figures have been based on EMCDDA’s definition 
of drug deaths. This broadened the inclusion criterion that had been used until then. In the 
period since 1996, Statistics Norway’s figures have been consistently higher than the figures 
from Kripos. However, if suicide (by means of drugs) and drug-related deaths among elderly 
people above the age of 65 are eliminated from Statistics Norway’s statistics, the difference is 
smaller, although still considerable in some years. The trends (up to 2009) were largely 
identical in both series of figures, however. 
Situation and development  
Table 3 shows that the figures for drug-related deaths peaked in 2000/2001. In the ensuing 
years, there has been a considerable reduction in the number of registered drug deaths. The 
reduction since the turn of the millennium is most probably due to the strong increase in the 
number of clients in Opioid substitution treatment - OST. Both the Statistics Norway figures 
and the Kripos figures appear to indicate that, after the reduction following the peak years of 
2000 and 2001, a certain stabilisation of the number of mortalities has occurred. The number 
of mortalities remains relatively high. 
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Table 3: Drug-related deaths 1991–2011. Total number of deaths and deaths broken down by 
gender. Figures from Kripos and Statistics Norway (underlying cause of death) 
1991–
2010 
Number of deaths according to 
Kripos 
Number of deaths according to Statistics 
Norway 
Men Women Total Men Women Total 
1991 74 22 96 66 22 88 
1992 78 19 97 81 23 104 
1993 77 18 95 76 17 93 
1994 102 22 124 105 19 124 
1995 108 24 132 114 29 143 
1996* 159 26 185 173 31 204 
1997 149 28 177 160 34 194 
1998 226 44 270 228 54 282 
1999 181 39 220 191 65 256 
2000 264 63 327 302 72 374 
2001 286 52 338 327 78 405 
2002 166 44 210 240 67 307 
 2003** 
 
 
134 38 172 193 62 255 
2004 
 
 
168 55 223 220 83 303 
2005 146 38 184 176 58 234 
2006 152 43 195 187 64 251 
 
 2007 162 38 200 217 58 275 
2008 148 31 179 210 53 263 
 2009 
 
 
 
146 37 183 222 63 285 
2010 n.a n.a  n.a 181 67 248 
 2011 n.a n.a  n.a 201 61 262 
 
        2012 n.a n.a  n.a *** *** *** 
 
                
Source: Kripos and Statistics Norway  
 
*The figures from 1996 onwards have been classified in accordance with a new revision. This means 
that figures from before and after 1996 are not directly comparable. Suicides in which narcotic 
substances were used are included from 1996. 
** STATISTICS NORWAY’s figures from 2003 onwards are based on WHO’s revised coding of causes 
of death. 
***Figures for 2012 are not yet available. 
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Of the 262 drug-related deaths in 2011 that were recorded by Statistics Norway, 207 (79%) 
deaths involved opioids with or without additional drugs, 74 deaths were due to heroin (X42, 
X44, X62, X64 + T401), 47 deaths were recorded with methadone poisoning as the 
underlying cause (X42, X44, X62, X64 + T403), and 68 with other opioids, either as 
poisoning or opioid dependency (X42, X44, X62, X64 + T402 or T400, F112). In addition, 
there were 18 deaths coded as related to ‘other synthetic opioids’ (X42, X44, X62, X64 + 
T404). The remaining 55 deaths broke down as follows: 21 psychostimulants (X41, X44, X61 
+ T436), 9 unspecified narcotic substances (X42, X44 + T406 or T409), 25 cases of 
dependency on other stimulants and dependency on multiple/other drugs (F152, F192), and 
zero deaths from cocaine (T405) and cannabis (T407). 
In 2011, 44 (16.8%) of the included deaths were coded as suicides (X62, X64), which is 
higher than the 10 per cent reported for 2010, but probably still a conservative estimate of the 
suicide rate. 
 
Figure 6: Drug-related deaths in 2011 broken down by substance. Number 
 
Source: SIRUS and Statistics Norway  
 
 
Comments 
• Many of the drug-related deaths are believed to be due to extensive multiple drug use.  
• Since 2007, the average strength of heroin seized by the police and customs in Norway 
has decreased from 36 per cent to around 15 per cent. During the same period, the 
proportion of heroin as the main intoxicant has been almost halved. However, more 
than four out of five drug-related deaths are still due to opioids. It seems that there 
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may be a gradual change in the preference for and/or availability of opioids among 
opioid users, and that this is also reflected in causes of death. Amphetamine and/or 
methamphetamine and/or cocaine were detected in 11 per cent of the deaths. 
• By the end of 2012, there were around 7,000 patients in OST in Norway. There were 
84 deaths from all causes among patients in OST in 2012, indicating a total mortality 
rate of about 1.2 per 100 person-years while in OST. The majority of deaths in OST 
were due to somatic causes and injuries. 
• Forty-seven deaths in 2011 were reported to be due to methadone, which is slightly 
higher than the level in 2010. The majority of methadone-related deaths occur among 
persons not enrolled in the OST programme. However, it is generally a challenge to 
differentiate between deaths caused by methadone and deaths where methadone was 
present in the blood at the time of death, but was not necessarily the cause of death. 
 
Age increasing  
Figure 7 shows that the proportion of drug-related deaths among people over the age of 30 has 
increased steadily over the years. In the 1990s, it had reached 60 per cent, according to 
Statistics Norway. These statistics show that, for the years 2000 to 2009, the proportion of 
drug-related deaths in the 30-plus age group was approximately 70 per cent on average. In 
2011, this age group accounted for 81 per cent of the drug-related deaths (212 persons). 
During the same period, the proportion over the age of 50 was 26 per cent of the total number 
of deaths (69 persons). Twelve of the deaths were in the 65-plus age group. The youngest age 
groups’ proportion of drug-related deaths has remained relatively stable, and one death was 
registered among persons under the age of 20 this year. 
For drug-related deaths, the mean age at the time of death has increased steadily in recent 
years, from around 35 years in the period 1996–2002 to 41.5 years in 2011. The increase in 
mean age at the time of death coincides with an expansion in the provision of OST in 
Norway, but the number of drug-related deaths has stabilised. It could be that OST contributes 
to the increase in the mean age, and, in that sense, increased age at the time of death can be 
seen as another positive outcome of the OST programme.  
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Figure 7: Drug-related deaths broken down by age group 1997–2011. Per cent 
 
Source: SIRUS and Statistics Norway 
 
 
Figure 8: Drug-related deaths broken down by age group 2011. Numbers 
 
Source: SIRUS and Statistics Norway  
 
 
Gender distribution: stable  
In 2011, 201 victims of drug-related deaths were male and 61 were female. The proportion of 
females was 23 per cent, which, seen in a longer-term perspective, seems to be within the 
‘normal range’. During the period 1997 to 2011, the proportion of women has varied between 
18 and 27 per cent (Figure 9). During the period 1980 to 1990, the average proportion of 
women was close to 22 per cent. 
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Figure 9: Drug-related deaths broken down by gender, 1997–2011. Per cent 
 
Source: SIRUS and Statistics Norway  
 
 
Confirmation of cause of drug-related deaths – high autopsy rate 
In 2011, there were 41,300 deaths in total in Norway. Of these, 3,072 underwent post-mortem 
examinations (autopsies). This means that Norway has an autopsy rate of about 75 per 1,000 
deaths overall. Among the 262 deaths recorded as drug-related deaths in this report, however, 
233 victims (89%) underwent an autopsy. Hence, the reported figures are in most cases based 
on toxicological confirmation of the drug-related death. This underlines that, in Norway, 
‘unnatural deaths’ among young adults are typically investigated by means of an autopsy 
(including toxicology) in order to confirm the cause of death. 
Geographical distribution  
In 2011, drug-related deaths were recorded in all the 19 counties in Norway (Figure 10). The 
concentration is particularly high in the Oslo area (Oslo and Akershus). The situation seems to 
have gradually improved in Oslo in recent years. The number of drug-related deaths in 
Hordaland county has increased significantly in recent years, and is now almost as high as in 
Oslo. This probably reflects the situation in Bergen, the second biggest city in Norway. No 
national statistics are available for drug-related deaths at the municipal level. However, 
SIRUS has made calculations (unpublished material) that show that drug-related deaths 
occurred in 87 Norwegian municipalities in 2009.  
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Figure 10: Drug-related deaths in 2011* broken down by county  
 
 
*n = 262  
Source:Sirus 
 
 
New study: Increased somatic morbidity after leaving opioid maintenance treatment  
A new cohort study among patients (Skeie et al, 2013) showed increased somatic morbidity in 
the first year after leaving opioid maintenance treatment (OMT).  
Background/Aims: Some patients in OMT leave treatment temporarily or permanently. The 
study investigated whether patients interrupting their OMT differed from non-interrupters in 
sociodemographic and drug-use characteristics and examined acute/sub-acute somatic 
morbidity among the interrupters, prior to, during and after OMT. 
Methods: Cohort design.  
Observation period: 
Five years prior to, up to first 5 years during, and up to 5 years after interruption of OMT. 
Participants:  
The sample (n = 200) comprised 51 OMT interrupters and 149 non-interrupters. Data on 
patient characteristics were obtained from interviews and OMT register information. Data on 
somatic morbidity were gathered from hospital records. 
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Measurements:  
Key patient characteristics among OMT interrupters and non-interrupters. Incidence rates of 
acute and sub-acute somatic disease incidents leading to hospital treatment (drug-related/non-
drug-related/injuries) prior to/during/after OMT. 
Results: 
Interrupters and non-interrupters did not differ in sociodemographic characteristics, while 
longer duration of amphetamine and benzodiazepine dependence predicted OMT interruption. 
Interrupters scored significantly higher on drug-taking and overdoses during OMT, but still 
had a significant 41per cent reduction in drug-related treatment episodes. After interruption of 
treatment, such episodes increased markedly and were 3.6 times more frequent during the first 
post-OMT year compared to the pre-OMT period (p < 0.001). This increase was highest 
during the first months after OMT interruption. There was no significant increase two to five 
years after interruption. 
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7 Responses to health correlates and consequences 
 
7.1 National overdose strategy 2013–2018 
In the white paper on a comprehensive drugs and alcohol policy, Report No 30 to the Storting 
(2011–2012) Se meg! (‘See me!’), the Government proposed developing a five-year strategy 
aimed at reducing the number of drug overdoses (Chapter 1). The Storting approved the white 
paper on 18 March 2013. This is the first time a national strategy of this kind will be 
implemented. Based on the Storting’s decision, the Directorate of Health has been tasked with 
drawing up a national strategy for reducing overdoses in collaboration with relevant agencies 
and organisations.  
EUR 1.25 million (NOK 10 million) has been allocated for the preparation of the strategy and 
implementation of measures in 2013 and 2014.  
The goal for the strategy is to stimulate the development of local strategies for municipalities 
with registered overdose fatalities. The strategy should have concrete goals and measures in 
the following areas:  
• responsibility for further development and coordination of the help services 
• clear assignment of responsibility when there is a risk of an overdose fatality 
• further competence-raising measures among particularly involved personnel, such as 
ambulance personnel and accident and emergency services staff 
• prevention of overdoses following discharge from institutions 
• necessary information for and involvement of next-of-kin 
• influencing the user culture (reducing the extent of injection) 
• further development of life-saving measures.  
Non-fatal overdoses can also lead to serious harm to health. The goal should therefore not 
only be to reduce the number of fatalities, but also to reduce the number of overdoses in 
general. Having survived an overdose can increase the risk of a second overdose, with a fatal 
outcome. The goal of the strategy should therefore be understood as to contribute to  
• reducing the number of overdoses 
• providing help as soon as possible after an overdose 
• reducing the number of overdoses with fatal outcomes 
• improving follow-up after non-fatal overdoses 
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Design  
• The final strategy document is being prepared by a broadly composed working group. 
It is expected to be finalised early in 2014. It will be based on a summary of research 
and discussions with key municipalities and important agencies/organisations. It is 
seen as important to ensure that the overdose strategy is not a short-term, isolated 
action plan, but is integrated in existing plans and measures. Measures have therefore 
been included that have already been implemented or that are being planned under 
other ‘headings’ that will or may have an overdose prevention effect. Continued 
development of treatment for opioid problems will be a priority, focusing on OST in 
particular. There will be continued focus on developing low-threshold OST in the 
municipalities and preventing dropping-out from detoxification, OST and residential 
treatment in interdisciplinary specialist treatment.  
The main focus of the strategy 
 The overdose strategy is intended to contribute to ensuring that existing measures have 
a stronger preventive focus.  
 It shall contribute to better coordination between existing measures for the prevention 
of overdoses (fatalities). 
 In particular, it shall contribute to such coordination by stimulating the development of 
local/municipal action plans.  
 It can initiate new measures in a few selected areas. 
 Several  important measures are already under way. 
Local overdose prevention strategies 
The nine municipalities with most overdose fatalities in 2011 (latest data) have been invited to 
apply for grants for the period 2014 – 2017. The aim is for the municipalities to investigate 
local overdoses in order to develop 
• local action plans  
• clear assignment of responsibility for coordinating help measures  
• clear assignment of responsibility when there is a risk of overdose fatalities and for 
follow-up after non-fatal overdoses 
• clear rules for the exchange of information when there is a risk of overdoses 
 
Encouraging inhalation instead of injection of heroin 
In October 2012, the Directorate of Health held a consultation meeting to discuss whether 
encouraging the inhalation instead of injection of heroin by injecting drug users would be a 
good contribution to the work of reducing the number of overdoses in Norway. 
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Representatives of user organisations, low-threshold services and researchers took part in the 
meeting. Few objections were raised, and it emerged that low-threshold health services and 
some user organisations already encourage the smoking of heroin. On assignment for the 
Ministry of Health and Care Services, the Directorate of Health has prepared a memo listing 
arguments for and against heroin smoking, particularly in relation to the discussion about the 
possibility of permitting inhalation in injection rooms. The reason for this was, among other 
things, a heated debate in the media after the then Minister of Health had recommended 
expanding the injection room scheme to include the inhalation of heroin.  
Distribution of naloxone nasal spray 
At the Ministry of Health and Care Services’ initiative, the National Directorate of Health 
submitted a memo in March 2013 recommending a trial scheme involving the distribution of 
nasal naloxone spray to heroin users, their next-of-kin and service providers. The Directorate 
of Health has tasked the Norwegian Centre for Addiction Research (SERAF) with developing 
and documenting such a project. Collaboration with a national naloxone project in Denmark 
has started. The project will run from 2013 until 2017. 
Collaboration with the Patient Safety Campaign 
Collaboration has been initiated with the Patient Safety Campaign with a view to, among 
other things, establishing a joint initiative targeting the correctional services.  
The campaign is already working on developing measures to prevent overdose deaths 
following discharge from interdisciplinary specialist treatment. 
Evaluation 
The Ministry of Health and Care Services has given SIRUS the task of evaluating the 
National Overdose Strategy. 
 
7.2 Low-threshold health services  
Government grant schemes have resulted in more municipalities establishing low-threshold 
health services for drug and alcohol users. An overview from 2010 showed that 48 
municipalities had established such services. The range of available services varies, but some 
of the cities offer very comprehensive services. The organisation, work methods and range of 
services vary from place to place, depending on the need and the available resources.  
Many of the low-threshold services also distribute syringes. In a survey carried out by SIRUS, 
24 municipalities stated that they had some form of needle exchange/distribution service. In 
2012, more than three million syringes were distributed at 36 distribution sites, just over half 
in the City of Oslo. Sales through pharmacies come in addition to this. Although the number 
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of distributed syringes has probably declined somewhat in the last two or three years, Norway 
is still among the countries that distribute most syringes. This can be seen as positive from an 
infection-prevention perspective: However, good availability contributes to continuing the 
practice of injection at the expense of methods of use that carry a lower risk of overdoses.  
Injection rooms  
In 2009, the Storting decided to make the provisional Act relating to drug injection rooms10 
permanent, which means that municipalities that wish to establish injection rooms have a 
legal basis for doing so. However, only Oslo has so far made use of the Act. Table 4 shows a 
strong increase in the number of registered users since the injection room opened as a trial 
scheme in 2005. The same applies to the number of injections per year. The increase is 
probably mostly related to the increased capacity. Very few overdoses have occurred in the 
injection room seen in relation to the high number of injections. This only applies to 
overdoses recorded while the users were on the injection room premises, however.  
 
Table 4: The injection room in Oslo. Statistics 2005–2012 
Year 2005 2006 2007 2008 2009 2010 2011 2012 
Number         
of registered users 300 400 674 1,224 1,665 2,211 2,556 2,775 
of users per year 277 297 486 923 - 1,484 1,539 1,557 
of injections per year 8,318 8,101 11,654 19,480 25,940 28,368 29,204 33,791 
of emergency calls (113) 35 36 70 122 155 164 155 196 
% overdoses of all 
injections  0.4 0.4 0.6 0.6 0.6 0.6 0.5 0.58 
 
Source: Agency for Welfare, Oslo  
 
  
10 Proposition No 59 to the Odelsting (2008–2009) concerning the Act amending provisional 
Act No 64 of 2 July 2004 relating to a Trial Scheme of Drug Injection Rooms (the Act 
relating to injection rooms) etc. 
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8 Social correlates and social reintegration 
 
See also Chapter 1.  
8.1 Housing 
A survey of homeless people conducted by the Norwegian Institute for Urban and Regional 
Research (NIBR) in 2008 (Dyb and Johannessen, 2009) found that there were around 6,100 
persons with no fixed abode in Norway. This was an increase compared with 2005. The 
survey shows that people with drug or alcohol problems account for 59 per cent of homeless 
people, four of five of those who experience long-term homelessness (more than six months), 
85 per cent of those who use emergency accommodation and 69 per cent of those who live in 
temporary housing arrangements. About 40 per cent suffer from mental illness. See also NR 
2011 Chapter 8.1.1 
Temporary housing  
Another report from NIBR (Johannessen and Dyb, 2011) presents and discusses findings from 
a survey on the use and quality of 24-hour accommodation and other forms of temporary 
municipal housing in 2010. The data were collected through a survey sent to 107 
municipalities and a survey of 145 temporary housing arrangements.  
Temporary housing was operationalised in eight categories: hotels/boarding houses; night 
shelters etc.; campsites/caravans/cabins; family centres; women’s shelters; temporary 
accommodation that the institutions are obliged to provide; 24-hour accommodation/hostels 
and other. Similar categories were used in the most recent nationwide survey of homeless 
people in 2008. 
People with drug or alcohol dependency and persons with a dual diagnosis are the groups that 
most municipalities state that they have provided temporary housing for in 2010. Seventy-one 
per cent of the municipalities state that persons with drug or alcohol dependency have stayed 
in such housing arrangements, and 58 per cent state that persons with drug or alcohol 
dependency and known or visible mental illness (dual diagnosis) have stayed in temporary 
housing. About half the municipalities state that persons with known or visible mental illness 
have stayed in temporary housing.  
‘Hotels/boarding houses’ are the type of temporary housing referred to by most 
municipalities, followed by ‘other 24-hour accommodation (hostels etc.)’, while just under 
half of the municipalities refer to ‘campsites’. Four out of ten municipalities refer to women’s 
shelters, two out of ten to night shelters.  
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The survey shows that it is more common for some groups to stay longer in temporary 
housing than others. This applies in particular to persons with drug or alcohol dependency and 
persons with a dual diagnosis. The most common length of stay for these two groups was 
more than three months in 29 and 27 per cent of the municipalities, respectively.  
In autumn 2011, the Government-appointed housing committee submitted Norwegian Official 
Report NOU 2011:15 Rom for alle (‘Housing for all’ – in Norwegian only). The committee 
assessed the need for housing for disadvantaged groups, and how state and municipal efforts 
should be organised. Calculations from the housing committee estimate that there is a need for 
at least 2,500 more suitable houses or apartments for persons with drug or alcohol problems 
and/or mental health problems and illnesses (500 per year in a five-year period). The 
Government will present a white paper on housing policy in 2013. One of the topics covered 
by the white paper will be targeted efforts in relation to persons who are unable to obtain 
housing themselves and to continue living in it, including people with drug or alcohol 
dependency and/or mental illnesses. 
The Norwegian Directorate of Labour and Welfare administers grants for social services and 
measures aimed at the disadvantaged. One of the grants, the grant for social housing work, 
aims to strengthen and develop the municipalities’ ordinary services in order to address the 
need for follow-up in relation to housing. 
Cooperation agreement 
In autumn 2011, five ministries entered into a cooperation agreement with the Norwegian 
Association of Local and Regional Authorities on social housing work (the Ministry of 
Labour; the Ministry of Children, Equality and Social Inclusion; the Ministry of Health and 
Care Services; the Ministry of Justice and Public Security; and the Ministry of Local 
Government and Regional Development). The agreement runs until the end of 2013. It obliges 
the parties to facilitate interdisciplinary and coordinated social housing work, including 
providing assistance for people who have difficulties obtaining housing for themselves and 
coping with normal living arrangements. Among other things, the agreement emphasises the 
establishment of housing for patients who are discharged from institutions in mental health 
care and drug and alcohol treatment (Ministry of Health and Care Services, 2012). 
 
8.2 Employment 
There are no reliable data showing the unemployment rate for people with drug problems, but 
the number who have little or no income from employment must be deemed to be high. For 
example, eight out of ten OST patients were not employed either part-time or full-time or in 
education in 2011. Thirty-nine per cent had disability benefit or retirement pension as their 
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most important income, while only eight per cent had their most important income from 
employment (SERAF 2012).  
Important measures in the Ministry of Labour’s area of responsibility include a trial scheme 
involving a qualification programme for at-risk groups. The programme was introduced as a 
nationwide scheme from 1 January 2010. Almost 5,000 participants completed the 
programme on schedule during the period 2008–2010, 40 per cent of whom moved on to 
employment, education or other work-related measures. The number of drop-outs has 
increased somewhat during this period, but it is still considered to be low. Persons with drug 
or alcohol problems are among those who meet the conditions for participation in the 
programme. However, there are no figures that show the proportion of persons with drug or 
alcohol problems among the participants in the qualification programme. Funding of the 
programme has now been included in the municipalities’ block grants. 
Drug and alcohol problems is one of the focus areas in the National Strategy Plan for Work 
and Mental Health. Several professional development programmes have been initiated, 
including Coping strategies leading to employment – drugs and alcohol and mental health 
problems and guidance and follow-up guides. In connection with the national budget for 
2012, the Government presented the document Job Strategies for People with Disabilities. 
Young people under the age of 30 with drug or alcohol problems can be included in the job 
strategy if their problems have led to permanent functional impairment. 
Many people with drug or alcohol problems who have been convicted and who are serving or 
have served their sentences, need services from NAV, among others. The cooperation 
between the correctional service and NAV is laid down in a central cooperation agreement 
that forms the basis for agreements between the parties at the regional and local level. The 
purpose is to lay the foundation for further development of cooperation, and to contribute to 
binding and systematic collaboration. 
The Government’s return-to-society guarantee was introduced in Report No 37 (2007–2008) 
to the Storting: Punishment that works – less crime – a safer society. It means that everyone 
will be guaranteed follow-up upon release. Based on the return-to-society guarantee and the 
cooperation agreement, NAV will provide services to inmates. The NAV office in the 
municipality where the prison is located will provide these services by agreement with and in 
cooperation with the NAV office in the inmate’s home municipality. For some inmates, it 
may be relevant to take part in work-related measures while serving a sentence in an 
institution, both in and outside prison. Some counties organise labour-market courses in 
prison in cooperation with the correctional service. To be able to participate in measures 
outside the institution, the inmate must have been granted day release, cf. the Execution of 
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Sentences Act. Whether an inmate is allowed to take part in such measures is decided on the 
basis of individual needs. 
Drug and alcohol advisers can play an important part in the reintegration process (see NR 
2009 Chapter 8.1.2). As part of the Action Plan 2007–2012, advisers were appointed in 30 
selected municipalities, and many of them are employed at the local NAV office. The 
intention is that drug and alcohol advisers will provide comprehensive follow-up for 
individual clients. This entails assistance aimed at limiting drug and alcohol use, obtaining 
suitable housing, treatment, orderly finances, help to handle debts, help to start meaningful 
activity or keep an ordinary job. The advisers’ comprehensive follow-up can include 
motivation, guidance, training in social skills, job-seeking assistance etc. The advisers refer 
clients to treatment and follow up clients in and outside measures. Some of them also carry 
out preventive work and information activities relating to drug and alcohol use. The drug and 
alcohol advisers also work in interdisciplinary teams. 
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9 Drug-related crime, prevention of drug-related 
crime and prison 
 
9.1 Drug law offences 
 
9.1.1  Legal basis and type of statistics 
Norway does not have separate legislation relating to drugs. Two acts apply in connection 
with the reporting, charging and prosecution of drug crimes: the Medicinal Products Act and 
the General Civil Penal Code.11 Statistics Norway is the Norwegian institution responsible for 
keeping statistics on drug-related crime in the judicial system. Four types of crime statistics 
are published annually (http://www.ssb.no/kriminalitet/): 
• Offences reported to the police 
• Offences investigated – clear-up rate – persons charged – recidivism figures 
• Penal sanctions – persons convicted – previous criminal offences 
• Imprisonments12  
The statistics do not contain information about the types and quantities of narcotic substances 
involved in prosecutions, however.  
Since 2010, statistics have been published about charges brought against persons, in addition 
to the two other main categories criminal offences and persons charged, which are already 
included in the statistics. The statistics for charges contain a complete overview of all criminal 
offences with which the persons in question were charged during the year.  
11 Minor drug offences that involve the use or possession of drugs are punished pursuant to the Act relating to 
Medicinal Products (Act No 132 of 4 December 1992) Section 24, which provides for a maximum sentence of up 
to two years’ imprisonment. Other drug crimes are punishable pursuant to Section 162 of the General Civil 
Penal Code (Act No 10 of 22 May 1902 with subsequent amendments). The General Civil Penal Code Section 
162 distinguishes between four degrees of gravity depending on the drug and amount involved and the nature 
of the offence in other respects. If a small quantity is involved, the offence is punishable by fines or 
imprisonment for up to two years. Aggravated drug crimes include the three other degrees of gravity. If a 
somewhat larger quantity is involved, the offence is punishable by imprisonment for up to ten years; if a 
substantial quantity is involved, the offence is punishable by imprisonment for between three and 15 years, 
and under particularly aggravating circumstances the punishment can be up to 21 years’ imprisonment, which 
is the maximum punishment under Norwegian criminal law. 
12 There are three key categories in these statistics: Prison population/inmates; new imprisonments, e.g. by 
type of offence and type of imprisonment; discharges, e.g. by prison time. 
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The police and the prosecuting authorities must have made a legally binding decision 
concerning a specific perpetrator (before any indictment and before a case comes to court), in 
order for Statistics Norway to define a charge and a person charged. A person suspected of 
having committed a crime may be given legal status as ‘charged’ at different times during an 
investigation. Persons who have been charged during an investigation but who did not have 
the status of perpetrator when the investigation was concluded are not included in the 
statistics. 
Since 2010, tables have also been published showing all persons charged in each crime 
category. Normally, the persons charged and pertaining information about them are broken 
down by their primary offence – i.e. the offence that, pursuant to the law, can lead to the most 
severe penalty. The new statistics show everyone charged with one or more offences, and not 
just those with a primary offence, in each of the crime categories. If a person is charged with 
more than one offence in a crime category, the person is classified on the basis of the primary 
offence in the individual crime category 
. 
9.1.2 Statistics 
Reported crimes  
According to Statistics Norway, a total of 45,900 drug crimes were reported in 2012. This is 
3,100 more than in 2011, and the highest number recorded since 2001.  
More drug crimes were committed in 2012 than the year before, including violations of both 
the General Civil Penal Code and the Act relating to Medicinal Products. In total, around 
21,600 drug crimes pursuant to Section 162 of the General Civil Penal Code, including 
aggravated drug crimes, were reported. The number of drug crimes pursuant to the General 
Civil Penal Code was almost on a par with 2010, the peak year in terms of reported drug 
crimes. The almost 23,500 violations of the provision of the Act relating to Medicinal 
Products concerning use and possession was the highest number since the early 2000s.  
The increase was greatest by far in Oslo. In addition to having the highest number, the county 
of Oslo also has the highest proportion of reported drug offences in relation to the population. 
Whether offences are solved and what penal sanctions are imposed vary greatly between 
different crime categories and types of offences. Drug crimes have the highest clear-up rate of 
all the crime categories, at 88 per cent, while crimes against property and vandalism have the 
lowest clear-up rates, at 22 and 19 per cent, respectively. 
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Charges 
More and more people arrested for drug offences 
In 2011, 13,185 persons (men: 83%, women: 17%) were charged with a drug crime as their 
primary offence, a considerably higher figure than in all previous years. That is 8 per cent 
more than in 2010 and 23 per cent more than in 2009. The increase and the record-high 
figures concern violations of both the General Civil Penal Code and the Act relating to 
Medicinal Products. The increase in the number of people charged with less serious violations 
of the Act relating to Medicinal Products as their primary offence was greatest from 2009 to 
2011 (as much as 38 per cent).  
 
 Table 5: Persons charged with a drug crime as their primary offence 2002–2011 
Year 2002  2003 2004 2005 2006 2007 2008 2009 2010 2011 
Men 8,012 7,915 8,093 8,049 8,357 8,657 8,560 8,777 10,102 10,938 
Women  1,930 1,904 1,825 1,853 2,053 2,200 1,996 1,954 2,098 2,247 
Total 9,942 9,819 9,921 9,902 10,410 10,857 10,556 10,731 12,200 13,185 
Source: Statistics Norway  
 
 
A total of 18,400 people were charged with one or more drug offences in 2011, and they were 
charged with a total of 39,100 drug offences. This means that drug crime accounts for almost 
22 per cent of all charges for violations of the law and roughly 41 per cent of all criminal 
charges. Those charged with drug crimes account for nearly half of all people charged with 
crimes, and as many as 62 per cent in the 25–29 age group.  
Of those charged with a drug offence as their primary offence in 2011, nearly 81 per cent 
were Norwegian nationals, which is about the same proportion as in the two preceding years. 
Norwegian nationals contributed most to the increase, with nearly 700 more offences in 2011 
than in 2010, but there were also 300 more non-Norwegians among those charged with a drug 
crime as their primary offence.  
Recidivism – highest among young men 
The statistics for recidivism among people resident in Norway show that 46.5 per cent of the 
79,500 persons charged in 2006 were charged one or more times in the course of the next five 
years. This proportion has steadily decreased in the last four recidivism surveys and was 49.6 
per cent for those charged in 2002.  
Broken down by crime category, the highest recidivism rate – 66 per cent – is found among 
those charged with drug crime as their primary offence. The corresponding proportion among 
those charged with violence was nearly 57 per cent, and 55 per cent among those charged 
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with crimes against property. Of all persons charged in 2006 with sexual crime as their 
primary offence, 37 per cent were charged for another offence during the period from 2007 to 
2011.  
Penal sanctions  
The number of penal sanctions where drug crime was the primary offence was 15,700 in 
2011. This is just over 5 per cent more than in 2010 and as much as 22 per cent more than in 
2009. Never before have so many penal sanctions been recorded with drug crime as the 
primary offence: in 2011, they accounted for more than 47 per cent of all penal sanctions in 
criminal cases (Figure 11). Seen in relation to the increase in population, however, the number 
of penal sanctions for drug crimes is still lower than in the peak year of 2001.  
In 2011, the number of penal sanctions where aggravated drug crime pursuant to Section 162 
second and third paragraphs was the primary offence was 816. This is the highest number 
ever recorded. However, less serious violations of the Act relating to Medicinal Products, 
such as use and possession of small amounts of drugs, contributed more to the increase in the 
total number of penal sanctions for drug offences from 2010 to 2011.  
 
Figure 11: Number of penal sanctions where drug crime was the primary offence 1999–2011 
 
Source: Statistics Norway  
 
 
The prosecuting authority decided more criminal cases than the courts. Around 10,900 cases 
where drug crime was the primary offence were settled by a fine without the case going to 
court. Of these cases, 6,400 violations of the Act relating to Medicinal Products were settled 
by a fine and registration in the criminal records.  
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Drug crime as the primary offence was the reason for nearly 2,000 of the unconditional prison 
sentences (both unconditional and partly unconditional/partly suspended). Of the offenders 
(cases, not persons), 205 were sentenced to imprisonment for use as the primary offence. This 
represents more than a twofold increase from 2009. However, these are often complex cases, 
where other, less serious offences are taken into consideration in the overall sentencing.  
 
Table 6: Unconditional prison sentence* as sanction for use and possession as the primary 
offence 2005–2011 
Year  2005 2006 2007 2008 2009 2010 2011 
Drug use  142 122 156 167 94 187 205 
Drug possession   37 39 20 32 25 46 47 
Total  179 161 176 199 119 233 252 
*Both unconditional and partly unconditional/partly suspended 
Source: Statistics Norway  
 
 
The majority of registered offenders in the less serious drug offences are Norwegian 
nationals, while foreign nationals are behind most of the aggravated drug offences. As of 10 
October 2012, 1,394 offences (suspected, charged or convicted) were related to Section 162 
second and third paragraphs of the General Civil Penal Code. Of these, 79 were related to 
Section 162 third paragraph, which concerns the most serious drug crimes. The offenders 
were Norwegian nationals in 942 of these cases, 28 of which were related to Section 162 third 
paragraph. Foreign nationals were responsible for 452 offences, 51 of which were related to 
Section 162 third paragraph (Kripos, 2013).  
 
9.2  Interventions in the criminal justice system  
As of 1 January 2011, there were a total of 3,866 inmates in Norwegian prisons, including 
those who served their sentence at home with electronic monitoring and those remanded in 
custody. Of all inmates at the start of the year, 30 per cent were serving sentences for drug 
offences, 22 per cent for crimes against property and 21 per cent for violent crimes as their 
primary offence. Of the 884 persons held on remand at the start of 2011, 37 per cent had drug 
crime as their primary offence. 
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9.2.1 Alternatives to prison  
Serving of sentences outside institutions pursuant to the Execution of Sentences Act 
Section 1213  
In 2012, 452 persons (2011: 526) were serving sentences under this system, 12 per cent of 
them women (Table 7). A total of 273 persons started serving their sentence in prison and 
were later transferred to an institution. The other 179 started serving their sentence in a 
treatment institution. It must be assumed that the majority had a drug problem at the time of 
imprisonment. 
In 2012, 41,529 days were served in an institution pursuant to Section 12, which is a 
substantial decrease in relation to 2011, but on a par with the years before (Table 8).  
 
Table 7: Number of sentences started pursuant to Section 12, 2004–2012 
 Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Men  297 379 388 396 431 457 443 466 396 
Women 32 59 51 61 74 84 68 60 56 
Total 329 438 439 457 505 541 511 526 452 
Source: The central administration of the Norwegian Correctional Service 
 
Table 8: Number of days served pursuant to Section 12, 2004–2011 
Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Men  26,302 34,474 37,137 37,835 40,150 35,651 35,981 41,343 37,013 
Women 2,235 3,786 4,347 4,224 4,841 5,963 4,796 4,344 4,516 
Total 28,537 38,260 41,484 42,059 44,991 41,614 40,777 45,687 41,529 
Source: The central administration of the Norwegian Correctional Service 
 
13 Section 12 states that ‘A sentence may in special cases be wholly or partly executed by 24-
hour detention in an institution if such detention is necessary for improving the convicted 
person’s capacity to function socially and law-abidingly, or there are other weighty reasons 
for doing so. The convicted person may be restrained against his or her will and brought back 
in case of escape, if necessary by force and with the aid of public authorities. The 
Correctional Services shall not decide on such execution if it is opposed to security reasons or 
there is reason to assume that the convicted person will evade the execution.’ 
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Suspended sentence with a programme for driving under the influence  
This sanction replaces the previous alcohol treatment programme. During the course of 2012, 
a total of 523 (2011: 573) suspended sentences were imposed on condition that the offender 
completed a programme for driving under the influence. A total of 85 per cent of the 
sentences were completed, and 81 per cent (2011: 77%) were completed without the 
conditions being breached or new crimes being committed. The statistics do not specify the 
types of drugs involved, however.  
Suspended sentence with drug courts  
Drug courts are an alternative to prison for people with drug and/or alcohol dependency who 
have been convicted of drug-related crimes. The participants regularly attend a day centre 
where rehabilitation services are provided by an interdisciplinary service team. The 
programme was originally a three-year trial project started in 2006 in Oslo and Hordaland 
counties. The project has been prolonged until the end of 2014 and will be evaluated by 
SIRUS. In 2012, 29 new sentences were implemented, 15 in Oslo and 14 in Hordaland.  
Community sentences 
Community sentences are often imposed for less serious offences. Community sentences were 
imposed in 552 cases involving drug crimes in 2011 (2010: 534). It is worth noting that 430 
of the sentences concerned drug crimes pursuant to Section 162 of the General Civil Penal 
Code, and as many as 100 concerned aggravated drug crimes pursuant to Section 162 second 
and third paragraphs.  
Serving of sentences with electronic monitoring 
The serving of sentences with electronic monitoring was passed into law by the Act of 29 
June 2007 No 83 relating to amendments to the Execution of Sentences Act. It entered into 
force on 1 August 2008. The Act means that convicted persons who are to serve unconditional 
prison sentences of up to four months, or who have four months left until being released on 
probation, can apply to serve their sentence with electronic monitoring. The convicted person 
must be resident in one of the six trial counties during the actual serving of the sentence and 
must live in suitable accommodation with the possibility of a telephone connection (see more 
in NR 2012, Chapter 9.2.1). In 2012, permission was granted for 887 new prison sentences to 
be served with electronic monitoring (2011: 920). So far, the vast majority are people 
convicted of traffic offences. No new data are available for the number convicted of a drug 
offence, but in 2010, drug crime as the primary offence accounted for nine per cent, or 76 
cases, of new imprisonments of this kind.  
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9.2.2 Units for mastering drug and alcohol problems 
A unit for mastering drug and alcohol problems is a reinforced unit in a prison. It functions as 
a separate unit that is specially adapted for inmates with drug or alcohol problems. The units 
are tasked with ensuring good cooperation between the correctional service, the specialist 
health service and the health and care services in prison. Steps also have to be taken to 
facilitate coordination between the correctional service, the specialist health service and the 
municipal services when inmates return to society.  
The specialist health service shall ensure that inmates’ patient rights are safeguarded through 
continued treatment in an institution or an outpatient clinic upon their release. The unit for 
mastering drug and alcohol problems shall motivate and prepare people with drug or alcohol 
problems for continued treatment after their release from prison. The rehabilitation can 
continue either by the inmate being transferred to serve his/her sentence pursuant to Section 
12 in a treatment or care institution, or by the inmate receiving treatment at an outpatient drug 
or alcohol clinic upon his/her release. Fourteen Norwegian prisons now have such units. The 
most recent one was opened in spring 2012. Experience from the establishment of the units 
indicates that they need both a clearer framework and better professional follow-up. The then 
Ministry of Justice and the Ministry of Health and Care Services therefore started work in 
2011 on a joint circular that clarifies the framework conditions and contains references to 
central regulatory provisions. In parallel, the correctional service’s central administration and 
the Directorate of Health have appointed a select committee that will produce a professional 
guide for the units for mastering drug and alcohol problems. The work will be concluded in 
2012. In order to monitor developments more closely, key figures are reported by the units on 
a monthly basis. The correctional service’s education centre has started the work of evaluating 
the units.  
In addition to units for mastering drug and alcohol problems, there is a Pathfinder unit for 
female inmates at Bredtveit prison (six places) in Oslo and one for men (20 places) in Oslo 
prison. The Pathfinder units offer rehabilitation and treatment for problem drug and alcohol 
users. They are a collaboration between the health authorities, the Tyrili foundation and the 
correctional service.  
9.3 Driving offences 
In 2012, drug analysis was carried out by the Norwegian Institute of Public Health (NIPH) in 
9,717 cases where drivers were suspected of driving while intoxicated. Of these, about 1,073 
breath tests were taken by the police locally, about 3,504 blood samples were analysed by the 
NIPH for alcohol only, while about 5,140 blood samples were analysed for alcohol, 
intoxicating drugs and narcotic substances. The NIPH routinely looks for over 40 different 
intoxicating drugs and narcotic substances, and detects an average of three drugs in the same 
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blood sample. For several of the substances, the detection limit has been lowered since legal 
limits for driving under the influence of substances other than alcohol were introduced on 1 
February 2012. See NR 2012 Appendix 1.  
In 2012, clonazepam was for the first time the second most commonly found substance (38% 
of all cases) after alcohol (59%). This is a marked increase compared with the previous year 
(24%), and it may be partly explained by the lowering of the detection limit. This means that 
clonazepam is now found in some cases where the substance would not previously have been 
detected. The NIPH most often finds clonazepam in combination with illegal substances 
(methamphetamine/amphetamine etc.), which indicates that the substance is increasingly 
being sold and used as a drug. Other substances that were frequently found were THC (35%) 
and methamphetamine (31%), followed by amphetamine (29%) and diazepam (22% of all 
cases). The analysis findings do not necessarily indicate whether or not the substance was 
unlawfully obtained.  
Some of the methamphetamine that is taken is converted into amphetamine in the body. Many 
of the blood samples that contain methamphetamine will therefore also contain amphetamine, 
even though the person in question has not actually used both drugs. The number of cases 
where amphetamine was found will therefore include both amphetamine used alone and 
amphetamine as a bi-product of methamphetamine. It is therefore misleading to simply add up 
the figures for amphetamine and methamphetamine. 
The fact that THC is found in a blood sample means that cannabis has been taken (usually 
smoked) shortly before the sample was taken, usually during the last few hours before driving 
(Norwegian Institute of Public Health). 
Table 9: Some findings of substances other than alcohol in blood samples from drivers 
suspected of driving under the influence in 2012. The number of blood samples for which a 
broad analysis was carried out 
Name of substance Example of name of medicine Explanation Number Per cent 
Clonazepam  Rivotril ®  1,935 38% 
THC Active agent in cannabis 1,821 35% 
Methamphetamine    1,574 31% 
Amphetamine    1,208 26% 
Diazepam Valium ® Vival ® Stesolid ® 1,116 22% 
Morphine  Heroin, Dolcontin®  217 4% 
Methadone  Methadone® 180 4% 
GHB  186 4% 
Buprenorphine Subutex®, Temgesic®, Subuxone® 151 3% 
Source: the Norwegian Institute of Public Health 
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10 Drug markets 
 
10.1 Availability  
Several factors must be emphasised when describing changes in availability. Seizures of 
illegal substances by the police and customs authorities are an important parameter in this 
context. However, the number of actual seizures and the quantities involved are affected by 
the internal priorities of and resources available to the police and customs authorities, and by 
surveillance methods and international cooperation. Big seizures in particular can be the result 
of surveillance and investigations carried out over time. The statistics can therefore show 
significant fluctuations from one year to the next, without this necessarily meaning that 
corresponding changes have occurred in terms of actual availability. The number of seizures 
must be deemed to be a better indicator of availability than the amount seized.  
Measured by seizures, the most common illegal substances are geographically widespread. In 
2012, all the 27 police districts made seizures of cannabis, BZD and amphetamines, whereas 
cocaine was seized in 25 districts and heroin in 23, quite similar to the situation in 2011. It 
must be emphasised, however, that the quantities vary greatly between the different police 
districts. For cocaine and heroin, the seizures are often small. For example, the amount of 
heroin seized was around ten grams or less in nine of the police districts, and in three of these, 
the total seizure amounted to as little as a user dose. The biggest markets are still the Oslo 
area and its surrounding regions, and in the counties of Hordaland and Rogaland, including 
the cities of Bergen and Stavanger. Moreover, the customs authorities in Østfold county make 
many large seizures, which can largely be explained by its proximity to the most important 
border crossings to Sweden, where large parts of the drug trafficking to Norway take place by 
road and by train from Denmark and the continent. 
 
10.1.1 The relationship between amphetamine and 
methamphetamine  
The seizure figures for the last few years are a clear indication that methamphetamine has 
partly taken over the market for amphetamines. Norway and Sweden seem to be among the 
European countries with the biggest market for methamphetamine, and Norway has topped 
the EMCDDA’s statistics for the number of seizures for several years running. Moreover, 
analyses of wastewater in Oslo carried out by the Norwegian Institute for Water Research 
(NIVA) show a high incidence of methamphetamine, higher than in most other cities that 
were part of the survey (Thomas et al., 2012). Next to THC (cannabis), methamphetamine is 
the illegal substance that was most often found in traffic cases in 2012 (Chapter 9.3.).  
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We know little about the prevalence measured on the basis of other parameters, however. 
Prevalence surveys among young people/young adults and the general population do not ask 
about methamphetamine in particular. This is because it is assumed that the respondents are 
unable to distinguish between the two amphetamines to any great extent. In 2012, as in 
previous years, the purity of analysed seizures varied considerably. The effect of strong 
amphetamine can therefore feel like methamphetamine, and vice versa. There are still very 
few, if any, indications that methamphetamine is in particular demand in a market in which 
amphetamine and methamphetamine are sold interchangeably and where users do not know 
what they get. The seizure figures can be interpreted to mean that methamphetamine mostly 
comes in addition to all the amphetamine that is smuggled in every year, and not so much as a 
replacement.  
 
10.2 Supply 
 
10.2.1 Smuggling routes to Norway  
Updated information from Norwegian Customs and Excise as of the first half-year 2013 
shows a marked increase in seizures of amphetamine/methamphetamine14 in the first half-year 
2013 compared with the corresponding period in 2012, and that the substances are smuggled 
to Norway from several European countries. Amphetamine is manufactured in the 
Netherlands, Belgium and Poland and in the Baltic states. It is assumed that 
methamphetamine seized in Norway is manufactured in the Baltics. A new trend that emerged 
in the first half-year is that the customs service has made seizures of amphetamine sent in the 
post from the Netherlands, Germany and China.  
Morocco remains the most important producer of hash seized in Norway. The customs service 
seized considerably less hash in the first half-year 2013 than in the corresponding period in 
2012. Only one major seizure was made in goods traffic from the Netherlands. The trend of 
smuggling small amounts of hash by plane and passenger car from Sweden, Denmark and the 
Netherlands continued in 2013.  
The customs service recorded an increase in both the number of seizures and the amount of 
marijuana seized. In addition to the Netherlands, countries in Eastern and Southern Europe 
such as Latvia, Poland, Romania and Greece have been identified as countries from which 
marijuana seized in Norway has been sent. The Netherlands has traditionally been a major 
producer of marijuana, but large plantations have also been uncovered in the Czech Republic. 
14 Seizures made by the customs service are included in the overall national statistics prepared by Kripos. See 
Chapter 10.3. 
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More and more marijuana is being produced in Albania, and marijuana found by the customs 
service in shipments from Romania and Greece may have been produced in Albania.  
The customs service still finds GBL and GHB in postal consignments from Poland, Thailand 
and China, and there is a slight increase in the number of seizures and the amount seized 
compared with previous years. The biggest seizures are still made from passenger cars 
crossing the border from Sweden.  
It is assumed that heroin smuggled to and sold in Norway is still manufactured in 
Afghanistan. The smuggling routes along the Balkans and the Silk Road further north through 
Iran and the Caucasus are still the most commonly used routes for smuggling heroin to 
Europe. The customs service seized considerably more heroin in the first half-year 2013 than 
in the preceding years. More seizures have been made of heroin smuggled inside the bodies of 
car passengers from Poland. They are assumed to form part of a Nigerian network that 
engages in organised crime in the Nordic countries. Germany, Denmark and Kosovo were 
also among countries from which heroin seized in Norway was sent.  
Khat is traditionally grown in East Africa and shipped to Europe by plane. Since the 
Netherlands made the substance illegal in January 2013, the UK is the only country where 
importing khat is legal. This makes the UK the most important country from which khat is 
sent to Norway. Despite the prohibition in the Netherlands, the number of seizures and 
amount of khat seized have increased – the amount has nearly doubled. Large consignments 
of khat are still smuggled by car from the Netherlands to Norway. Khat is also reloaded in the 
south of Sweden and in Denmark before being transported to Norway.  
The customs service has never seized as little cocaine as in the first half-year 2013. There 
have been no changes in production and smuggling routes from producing countries to Europe 
that can explain this decline. The seizures made have often been found in postal consignments 
from the European continent (the Netherlands, Spain, Belgium and Germany). There was one 
serious case in which cocaine was smuggled inside the body of an air passenger from the 
Netherlands. 
The customs service still uncovers large quantities of tranquilisers. The trend of smuggling 
Rivotril from Hungary, directly or via Sweden and Denmark, continued in 2013. Large 
amounts of diazepam are seized, especially from Thailand. Most of it is smuggled by post and 
by courier, while one large seizure was made in a maritime container shipment in the first 
half-year.  
The customs service seizes ecstasy in the form of tablets. In the first half-year, the biggest 
seizures were made in postal consignments, primary from Germany and the Netherlands. The 
production of ecstasy in Europe seems to have increased again, following a period when the 
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precursor PMK used in the production of the active agent MDMA has been scarce. An 
increasing number of seizures by the custom service of MDMA in powder form confirms that 
its availability has been restored. The seizures have primarily been made in postal 
consignments from the Netherlands, but also from Germany, Belgium and Spain. 
New psychoactive synthetic substances are a priority area for customs officers. However, a 
decline was recorded in the number of seizures of synthetic cannabinoids in the first half-year 
2013 compared with the first half-year 2012. The amendments to the Regulations relating to 
narcotics of February 2013, whereby generic control of seven groups was introduced, may 
have contributed to the decline. The seizures made by the customs service were mainly found 
in postal consignments from the UK and the Netherlands, as well as from China and the USA. 
On the other hand, the number of seizures and quantity of psychoactive substances seized 
have increased dramatically, mainly in shipments by post and courier from the Netherlands, 
China and Spain. The fact that the Regulations relating to Narcotics were amended to include 
control of groups of substances/compounds has probably led to an increase, since the customs 
service can now register these substances as drugs, and not as medicinal 
products/pharmaceutical substances as before (Personal communication, Directorate of 
Customs and Excise Enforcement Department, Anti Smuggling Section).  
 
10.2.2 Criminal networks  
The report Den organiserte kriminaliteten i Norge – trender og utfordringer 2013–2014 
(‘Organised crime in Norway – trends and challenges 2013–2014’) (Kripos, 2013) describes 
different international groups that, in the police’s opinion, are behind a large part of the 
importation and distribution of drugs in Norway.  
 
Baltic and Polish networks 
Lithuanian groups seem to be the main suppliers of methamphetamine to Norway, while they 
are also associated with other drugs. Extensive sales of amphetamine and/or 
methamphetamine by Lithuanian and Polish nationals is reported by many police districts. 
People from Lithuania and Poland who have permanent residence and legitimate work in 
Norway are deemed to be important points of contact for Lithuanian and Polish criminal 
networks.  
 
Networks from the Balkans 
The Balkans are known as a hub for the smuggling of different types of drugs to and from the 
EU, especially heroin, but increasingly also other types of drugs. Europol reports that 
Albanian-speaking groups collaborate with Lithuanian groups on heroin smuggling from 
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Central Asia to Western Europa. Several police districts report activities relating to the import 
and distribution of hash, marijuana, amphetamine, cocaine and heroin that can be linked to 
networks from the Balkans. Criminal networks from the West Balkans and Turkey could 
become more active in other European countries as a result of Bulgaria and Romania’s 
accession to the Schengen Area.  
Moroccan networks 
Moroccan networks have a central role in the importation of hash to Norway. They have 
proved adept at collaborating with different criminal gangs in Norway.  
 
Vietnamese networks 
The Vietnamese community in Europe is involved in extensive marijuana cultivation in 
several European countries, and indoor plantations are traditionally organised in a hierarchic 
structure. Several Norwegians nationals of Vietnamese origin have been known to cultivate 
marijuana in Norway. Close ties have also been found between the Vietnamese communities 
in Norway and the Czech Republic. People of Vietnamese origin who cultivate marijuana 
usually run several small plantations. 
Somali networks 
Use of the stimulant khat is part of the Somali culture. The use of khat in the Nordic countries 
and North-western Europe is most widespread in areas in which large Somali communities 
have settled. Khat is usually smuggled to Norway by Somali couriers by land, while couriers 
who arrive by plane are often European nationals. The Somali community is also associated 
with the sale of relatively large quantities of heroin to the open drug scene in Oslo.  
West African networks 
Criminal groups from West Africa, especially Nigeria, have been associated for many years 
with the smuggling of cocaine and heroin in particular. Statistics showed a ten-fold increase 
from 2000 to 2009 in the number of drug offences for which people of West African descent 
were either suspected, charged or convicted. The number of cases doubled from 2008 to 2010 
(Kripos, 2013).  
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10.3 Seizure statistics 
  
Drug statistics from the National Crime Investigation Service (Kripos) are national statistics 
of seizures made by both the customs service and the police. The number of drug cases15 has 
increased by 6 per cent from 2011 and has now reached an all-time high (Figure 12). There 
were 28,048 cases in 2012, compared with 26,391 in 2011. The fact that the number of cases 
has increasing may be due to increased importation and availability, but it is probably also a 
result of the police and customs service’s activities and priorities during the year in question.  
 
Figure 12: Number of drug cases registered by Kripos 2003–2012 
 
Source: Kripos 
 
Main trends 
 Although the number of drug cases increased for the fourth year in a row, the seizures 
do not represent record-high quantities, except in the case of benzodiazepines. 
 Even though traditional drugs dominate the drug market, new synthetic substances are 
seized all the time. In 2012, Kripos identified 30 new substances that had previously 
not been seized in Norway. Synthetic cannabinoids dominate among the new synthetic 
15 By case is meant an assignment logged by Kripos. The number of cases is irrespective of 
the use of the terms use, possession, sale and import in the prosecution. This means that an 
offence is only registered as one case by Kripos. 
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substances seized in the past two or three years. Of these, AM-2201 is currently the 
one most frequently seized. There is also an increase in hallucinogenic 
phenethylamines. Some variants with a particularly powerful effect are distributed as 
pieces of paper with an appearance similar to LSD. 
 Several different substances are more and more often seized in the same case. It 
appears that the users increasingly use several different substances and, in part, also 
consider some substances as substitutes for each other. Together with the frequent 
seizures of new synthetic substances, this indicates increased multiple drug use and 
experimentation. 
 Seizures of cannabis are increasing in step with general developments in seizures and 
account for just over one-third of the total number of drug seizures in Norway. While 
the number of seizures of hash is relatively stable, there is a marked increase in 
seizures of marijuana and cannabis plants. In the early 2000s, hash accounted for 
approximately 90 per cent of cannabis seizures, but it now accounts for 70 per cent, 
while marijuana and cannabis plants account for as much as 30 per cent. This 
development may be due to extensive and increasing production of cannabis in 
Norway. 
 More and more benzodiazepines are seized, especially tablets containing clonazepam 
and diazepam. As many as 60 per cent more tablets were seized in 2012 than in the 
year before. This is the largest quantity ever seized in a year, even though more 
seizures were made in 2002. The illegal importation of diverted legal medicinal drugs 
accounts for a substantial proportion of the seizures. 
 The number of seizures of amphetamine/methamphetamine is still high. Although 
slightly fewer seizures were made in 2012 than in 20xx, a larger quantity of 
amphetamine/methamphetamine was seized than in the two preceding years. Fewer 
seizures were made in 2012 than 2011 of PMMA, which is sold on the amphetamine 
market and has caused a number of deaths. Whether this is a trend that will continue is 
too early to say, however. 
 Fewer seizures were also made of heroin than in the preceding years. Some large 
seizures resulted in higher quantities, however. 
 Both the number of seizures and the amount of cocaine seized increased somewhat in 
2012 compared with 2011. If we look at the development in cocaine seizures over a 
five-year period, however, the number of seizures and the quantities seized have 
remained stable. 
 There are still great variations in the purity of amphetamine/methamphetamine, heroin 
and cocaine, from very weak (< 1%) to completely pure qualities. There is also great 
variation in typical street seizures. Mixtures with other drugs are frequent. 
 In the last few years, traditional ecstasy with MDMA as the active agent has been 
scarce in Norway, as in other countries. This is due to the fact that the trade in 
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chemicals used in the traditional manufacturing method has been regulated through 
international agreements. New manufacturing methods using other chemicals have 
been established, however, and an increasing number of seizures is being reported all 
over Europe. Tablets containing MDMA, often of high purity, are becoming 
increasingly common in Norway as well. At the same time, substitutes containing 
other active agents, such as piperazines, have decreased further and appear to be 
disappearing from the market. 
 GHB and GBL still account for a small proportion of overall drug seizures, but the 
number of seizures is steadily increasing. 
 Seizures of active agents, ampoules and other items that can be linked to illegal 
domestic manufacturing of doping substances were made in 2012 as well. 
 
Development in seizures for individual substance groups 
The development in the number of seizures16 and quantities seized for individual substance 
groups is shown in the tables below. The data are based on information available as of 
September 2013, but uncertainty is still attached to some of the figures, since not all analyses 
have been completed for the 2012 drug cases. In general, however, little change is expected in 
the quantities and number of cases when the seizures are verified by chemical analyses, and 
the effects on the main trends are expected to be negligible. About 60 per cent of the drug 
cases are minor cases that are settled by a fine without the type of substance being verified by 
analysis. In these cases, the assumed drug type forms the basis for the statistics. In today’s 
drug market, with many new psychoactive synthetic substances, however, the sources of error 
in connection with this information will be greater than before.  
 
 
 
 
 
16 Seizure: A case can often involve several seizures. It may involve different types of 
substances, or the seizures have been made in different places and at different times. 
Individual packages containing the same type of drug are regarded as one seizure if the 
seizures were made at the same time and place, however. 
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Table 10: Amounts seized for the most relevant drugs 2006–2012* 
Year 2006 2007 2008 2009 2010 2011 2012 
Cannabis (kg) 1,544 853 1,732 2,588 1,182 2,981 2,052 
Amph./methamphetamine 
(kg)  386 559 362 431 288.9 237.9 316.8 
Other stimulants (units) 1,603 1,979 2,796 3,469 19,089 + 24 kg 
9,302 + 
7.7 kg - 
Heroin (kg) 93.0 8.0 55.2 130.1 102 14.6 45.2 
Other opioids (tablets) 15,685 11,906 11,193 15,186 19,724 13,519 10,903 
BZB (units) 1,019,710 730,443 310,435 671,232 903,692 803,653 1,320,257 
Cocaine (kg) 40.5 95.0 76.8 61.1 94 48.1 66.8 
Ecstasy (units) 28,636 78,725 30,678 22,700 3,969 5,495 6,579 
Psilocybe mushrooms (kg)  0.84 1.36 0.5 1.66 2.0 2.6 2.67 
LSD (units) 226 26 245 510 173 885 1,388 
GHB/GBL (ltr) 45.5 100.9 257.3 213.4 490 524 376 
Synthetic cannabinoids 
(kg)     0.003 10.4 5.9 
* The data for 2010–2011 have been corrected as of September 2013 for several drugs after final 
analyses have been carried out.  
Source: Kripos 
 
Table 11: Large drug seizures pursuant to Section 162 third paragraph of the General Civil 
Penal Code in 2008–2011 
Drug type Number 2008 
Number 
2009 
Number 
2010 
Number 
2011 
Amphetamine/methamphetamine (threshold: 
seizures > 3 kg) 14 21 12 10 
Cocaine (threshold: seizures > 3 kg) 4 4 3 4 
Ecstasy (threshold: seizures > 15,000 tablets) 0 1 0 0 
Cannabis (threshold: seizures > 80 kg) 3 6 2 7 
Heroin (threshold: seizures > 0.75 kg) 16 32 29 4 
Benzodiazepines 1 0 0 0 
Total 38 64 46 25 
Source: Kripos 
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Table 12: Number of seizures in the period 2006–2012 broken down by type of drug* 
Drug type 2006 2007 2008 2009 2010 2011 2012 
Cannabis 11,221 9,952 10,599 11,754 14,372 15,141 15,751 
Amph./methamph. 5,819 5,507 5,153 5,775 7,714 7,221 6,801 
Heroin 1,087 1,204 1,145 1,430 1,575 1,314 1,277 
Benzodiazepines 4,500 4,058 3,451 3,796 5,089 5,185 5,629 
Painkillers/ opioids 1,161 959 936 1,078 1,223 1,240 1,277 
Cocaine 726 909 854 804 877 815 860 
Ecstasy 411 421 309 110 79 200 274 
LSD 28 13 15 26 30 31 83 
GHB/GBL 122 188 173 321 432 500 583 
Psilocybe mushrooms 82 77 54 75 114 104 144 
Synthetic cannabinoids      9 186 262 
* The data for 2010–2011 have been corrected as of September 2013 for several drugs after final 
analyses have been carried out. 
 Source: Kripos 
 
 
Comments on individual drugs 
Cannabis: The amount of cannabis seized in 2012, 2,052 kg, breaks down as follows: 
approximately 1,605 kg of hash (78%), 314 kg of marijuana (15%) and 133 kg (6%) of 
cannabis plants. The breakdown differs from 2011 in that the proportion of hash is lower 
while the proportion of marijuana has doubled. The amount of plants is less than half 
compared with 2008, when the police uncovered particularly many ‘cannabis plantations’. 
The number of seizures of cannabis plants remains relatively high, however (2012: 364, 2011: 
381, 2010: 378). It is reasonable to believe that small-scale cultivation activity accounts for a 
substantial proportion, and thus to assume that domestic production is a significant cause of 
the spread of marijuana. 
Amphetamine and methamphetamine: The number of seizures of amphetamine in 2012, 
2,529, was lower than in 2011, and much lower compared with 2010, while the number of 
seizures of methamphetamine, 4,272, was on a par with 2010–2011.  
The proportion of methamphetamine compared with amphetamine culminated in 2009, but it 
was nevertheless estimated to be as high as around 62 per cent in 2012 (Table 13).  
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Table 13: Proportion of seizures of methamphetamine in relation to amphetamine 
Year 2006 2007 2008 2009 2010 2011 2012 
% 
Methamph. 26% 35.3% 43.5% 64.3% 56% 60% 62.4% 
Source: Kripos 
 
Heroin: The quantity seized in 2012, 45 kg, is not particularly large compared with the peak 
years 2004 (129 kg) and 2009 (130 kg). The number of seizures, which is a better parameter 
of prevalence, has been far more stable. Oslo Police District made more than half of all the 
seizures of heroin in 2012. 
Painkillers, medicinal drugs classified as narcotics (opioids): No major seizures of these 
medicinal drugs were made in 2012. Several of the cases concerned illegal importation via 
internet shopping, but the number of tablets in each seizure is relatively small. It is once again 
buprenorphine (Subutex) and codeine (e.g. Paralgin forte) that dominate the statistics. 
Methadone and buprenorphine have increased their share of seizures from approximately 52 
per cent to 67 per cent in three years. 
Ecstasy is traditionally defined as containing the substances MDA, MDMA, MDEA and 
MBDB. Of these, MDMA has almost completely dominated seizures for more than 20 years. 
Until 2008, no other substance accounted for a substantial part of this tablet market. Then, 
however, MDMA was largely replaced by other drugs, mainly mCPP (1,3-
chorphenylpiperazine), a drug that was included on the list of narcotic substances in 2010. 
There has been a sharp decline in both the quantity and the number of seizures of ‘ecstasy 
tablets’ in recent years, but data for 2012 show that MDMA is once again on the increase in 
Norway.  
GHB and GBL: Although the number of seizures of GHB and GBL does not account for more 
than approximately 1.5 per cent of the total, there has been a considerable increase in both the 
quantities seized and the number of seizures. However, we cannot exclude the possibility that 
the chances of GHB/GBL being detected is lower than for other drugs, since the appearance 
and effect of GHB/GBL and alcoholic beverages are very similar. This could mean that the 
seizure statistics fail to reflect their actual prevalence. 
New synthetic drugs  
In 2012, 92 new synthetic drugs were reported to the EMCDDA’s Action on New Drugs 
programme. The number is record-high and has tripled since 2010. Thirty of the drugs were 
registered in Norway for the first time, which is also a record number. Synthetic cannabinoids 
dominate. As Table 14 shows, there was a clear preponderance of AM-2201 in the seizures 
made in 2012.  
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Table 14: Types of seizures of synthetic cannabinoids in 2012. Numbers and amounts* 
 Substances  Number of cases registered  Total amount  
AM-2201 64 2486g 
AM-2233 7 225g 
AM-694 1 0,9g 
JWH-018 20 96g +980 units 
JWH-073 2 5,0g 
JWH-122 10 43g 
JWH-210 4 3,0g 
JWH-250 1 3,5g 
MAM-2201 2 5,0g 
RCS-4 3 2,5g 
STS-135 1 4,9g 
UR-144 6 96g 
5F-AKB48 2 4,5g 
5F-UR-144 6 27g 
AB-001 1 0,2g 
*Preliminary data 
Source: Kripos 
 
10.4 Purity/potency/composition of illegal drugs and tablets 
 
See data in Standard tables 14 and 15. 
Table 15 shows that the average purity of heroin base continues to fall. An average purity of 
13 per cent is the lowest ever measured. As in previous years, paracetamol and caffeine were 
found in a number of seizures, in addition to depressants such as benzodiazepines, primarily 
alprazolam. A typical mixture can contain 5–10 per cent heroin and a large proportion of 
alprazolam, which causes stronger and more untraditional intoxication symptoms. Such 
mixtures are registered both in heroin seized at the border and in seizures made in the user 
milieus. 
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Table 15: Average purity of brown heroin 2005–2011 
Year 2005 2006 2007 2008 2009 2010 2011 2012 
Purity percentage  26% 30% 36% 31% 25% 21% 15% 13% 
Source: Kripos 
 
The average purity of amphetamine was about 20 per cent, and 33 per cent for 
methamphetamine. For both substances, the average purity has declined in the past three years 
(table). As before, the purity of analysed seizures varied substantially in 2011, from less than 
one per cent to 96–99 per cent. 
 
Table 16: Average purity of amphetamine and methamphetamine 2010–2012 
Year 2010 2011 2012 
Amphetamine 28% 25% 20% 
Methamphetamine 44% 38% 33% 
Source: Kripos 
 
The average purity of seized cocaine decreased steadily until 2009, from 69 per cent in 2000 
to 25 per cent in 2009. The level has since been between 31 and 37 per cent. Phenacetin, 
xylocain and caffeine are often found as additives. 
 
Table 17: Average purity of cocaine 2000 and 2004–2012 
Year 2000 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Purity percentage  69% 47% 50% 35% 39% 37% 25% 37% 31% 33% 
Source : Kripos 
 
 
As regards the THC content in the cannabis seizures, there are insufficient data for 2012 
concerning cannabis resin (hash). For herbal cannabis (marihuana), the average THC content 
is estimated to nearly 11 per cent, while it was around six per cent in 2010–2011.  
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http://www.regjeringen.no/en/dep/hod.html?id=421 
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